The Peter Attia Drive - November 16, 2026


#416 ‒ The science of mitochondria: their role in health, aging, and disease, and what the evidence says about drugs and supplements aimed at improving their function | Navdeep Chandel, Ph.D.

#415 ‒ AMA #91: Understanding lab testing: what blood work can and cannot tell you about your health and disease risk

Episode Stats


Length

2 hours and 6 minutes

Words per minute

179.55

Word count

22,717

Sentence count

1,949

Harmful content

Misogyny

3

sentences flagged

Toxicity

1

sentences flagged

Hate speech

3

sentences flagged


Transcript

Transcript generated with Whisper (turbo).
Misogyny classifications generated with MilaNLProc/bert-base-uncased-ear-misogyny .
Toxicity classifications generated with s-nlp/roberta_toxicity_classifier .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
00:00:00 Hey, everyone. Welcome to the Drive podcast. I'm your host, Peter Atiyah. This podcast,
00:00:16 my website, and my weekly newsletter all focus on the goal of translating the science of longevity
00:00:21 into something accessible for everyone. Our goal is to provide the best content in health and
00:00:26 wellness. And we've established a great team of analysts to make this happen. It is extremely
00:00:31 important to me to provide all of this content without relying on paid ads to do this. Our work
00:00:36 is made entirely possible by our members. And in return, we offer exclusive member only content
00:00:42 and benefits above and beyond what is available for free. If you want to take your knowledge of
00:00:47 this space to the next level, it's our goal to ensure members get back much more than the price
00:00:53 of a subscription. If you want to learn more about the benefits of our premium membership,
00:00:58 head over to peteratiamd.com forward slash subscribe. My guest this week is Nav Chandell,
00:01:06 returning for his second conversation on The Drive. I believe Nav was on in late 2018 or early
00:01:12 2019. Nav is a distinguished professor of medicine, biochemistry, and molecular genetics
00:01:17 at Northwestern University, where he studies mitochondrial biology and the role mitochondria
00:01:22 play in aging and chronic disease. He's one of the most thoughtful scientists I know in this space,
00:01:27 especially when it comes to separating what we think we know about mitochondria from what the
00:01:31 data actually support. And of course, everybody knows that mitochondria is almost a laughable
00:01:37 buzzword at this point in health circles. So I thought it would be really important to have on
00:01:43 the world's expert on this topic so that we could separate signal from noise. In this episode,
00:01:47 we discuss what mitochondria actually do beyond ATP production, which I think is what everybody
00:01:52 understands, why their real job is often misunderstood, how mitochondria regulate
00:01:57 signaling through reactive oxygen species, and why that matters for immune function,
00:02:03 the role of mitochondrial metabolites in epigenetics, gene regulation, and cellular
00:02:07 adaptation, how mitochondrial DNA can trigger inflammation, and how that intersects with aging,
00:02:13 what, quote, mitochondrial dysfunction really means, and why it's often used too loosely in
00:02:19 aging conversations, why metformin remains one of the most interesting drugs from mitochondrial
00:02:23 biology despite decades of use, how metformin actually behaves in the body, including its
00:02:29 distribution, tissue level effects, and gut-centric mechanisms, the relationship between mitochondria
00:02:35 inflammation and environmental stressors like pollution, a practical rundown of popular
00:02:40 mitochondrial supplements and what NAV thinks the evidence does and doesn't support for each of them,
00:02:46 where compounds like urolethan A and alpha-ketoglutarate fit in under this broader
00:02:51 mitochondrial conversation, the mechanistic appeal, and real-world limitations of interventions like
00:02:57 methylene blue and hyperbaric oxygen. Going into this podcast, I thought I understood most of what
00:03:04 the mitochondria did, and I have to say I came out of this scribbling down many notes realizing
00:03:10 that my own understanding of this space expanded significantly. And so for that reason, I'm pretty
00:03:16 confident everybody listening to this is going to share my enthusiasm for this topic. So without
00:03:21 further delay, please enjoy my conversation with Nav Chandel. Nav, good to see you again,
00:03:31 my friend. Great to see you. Thanks for the invite. Thank you for coming down. I suspect
00:03:35 that a number of people listening to us today may have not heard us speak eight, six, seven years
00:03:41 ago. I don't remember. If they did, I'm sure it's easy to forget. And there's so much new stuff to
00:03:46 talk about. But I always like to kind of ground people in what the mitochondria are. Unfortunately,
00:03:52 mitochondria has become one of the top 10 buzzwords on social media. So there's no chance
00:03:58 that anybody listening or watching us hasn't heard the term. But that second and third order
00:04:04 understanding might be a little foggy. And given that we're going to talk so much about mitochondrial
00:04:09 health, which is a big buzzword, mitochondrial boosters, and all these other things, we do need
00:04:14 to ground this discussion in what mitochondria are. So take it away. Yeah. Thanks again, Peter.
00:04:20 I agree with you. I think it's not only mitochondria, but the other big buzzword is
00:04:24 mitochondrial dysfunction. That's the real buzzword which you hear over and over. So if you're going
00:04:29 to talk about mitochondrial dysfunction, you're absolutely right. Why don't we start with
00:04:32 mitochondrial function. Now, mitochondria do a lot of things, and I'm sure my colleagues will be
00:04:37 like, Nav, you didn't discuss X, Y, and Z, so we're not going to discuss how mitochondria are
00:04:43 made or degraded and how many different kinds of mitochondria they may be. There's a lot we can
00:04:48 cover. We're going to focus on one thing, mitochondrial function. What do mitochondria
00:04:53 functionally do? Most people know it as the powerhouse of the cell because it makes the ATP,
00:04:59 and that gives you the power for your muscles, your neurons to fire. And for a long time,
00:05:06 most of us just thought about mitochondria as an ATP generator. So when mitochondrial
00:05:11 dysfunction comes, does it happen in aging or in heart failure? It's you don't make enough ATP.
00:05:17 Now remember, glycolysis can also make ATP, but mitochondria is much more efficient and can give
00:05:23 you a lot more. So very simple, and all the great theories around mitochondrial dysfunction related
00:05:30 to any particular disease, if it is causal, or the natural aging process is all about ATP. Well,
00:05:36 I'm here to tell you, we're not going to talk about the ATP, because there's a lot more that do.
00:05:41 So just to back up, the electron transport chain generates a protomotive force, basically a voltage,
00:05:48 which can be harnessed to make ATP. That process is coupled to something called the Krebs cycle
00:05:55 or the TCA cycle. And it turns out that the TCA cycle is the anabolic engine also in your cells.
00:06:03 So mitochondria do two things. They make ATP, and they can make the building blocks,
00:06:07 the metabolizer, the building blocks for new lipids, new nucleotides like DNA, RNA,
00:06:14 Okay? Amino acids for the building blocks of the protein. And that's settled law. People forgot
00:06:20 that mitochondria is an anabolic engine. We'll get into it with cancer in a second. So that's
00:06:25 what classically the great biochemist of the 20th century taught us. And that's, like I said,
00:06:31 it's in your textbooks. What has changed in the last 30 years, and I think I've been part of that
00:06:37 revolution, is that mitochondria also communicate. They're just not an organelle sitting on the side
00:06:43 and things like mTOR, when they get activated or deactivated, mTOR is a big decision-maker
00:06:49 of metabolism. Your genes being turned on and off, they're deciding cell fate, how a cell
00:06:54 becomes what it does. And mitochondria just sitting there giving you ATP, giving you metabolites,
00:07:00 it has no decision-making properties. Well, that's changed.
00:07:05 Can we back up for one sec now and just give folks maybe a sense of size and scale? So
00:07:10 are there any cells in the body that don't have mitochondria in them?
00:07:12 Red blood cells.
00:07:13 Okay. Absent red blood cells, when you consider all the other cells which have mitochondria,
00:07:18 what is the approximate cellular density of mitochondria?
00:07:21 It depends.
00:07:21 Yeah. So let's talk about a neuron. A neuron might have approximately how many?
00:07:25 Actually, I don't know these numbers, to be honest with you. The hepatocytes are full of them.
00:07:30 We're talking thousands.
00:07:31 Yeah, for sure.
00:07:32 Maybe more.
00:07:33 Maybe more. But again, instead of worrying about are they dense or they're not dense,
00:07:38 I think if you look at them from what they're doing, there's the ATP, there's the metabolites.
00:07:44 But what I really want to get into is the third aspect, which a few mitochondria could probably
00:07:50 fulfill. And so that way, you don't have to always think about mitochondrial biogenesis. I think
00:07:55 that's why you're asking this question. We're thinking of it in terms of supply and demand
00:07:59 mismatch, for example. So are they being paired to cells in density based on energy need or
00:08:07 metabolite need. Because for example, a hepatocyte doesn't actually need much ATP,
00:08:12 but it needs a lot of anabolic precursor. It makes glucose, for example.
00:08:18 I assume that in the hepatocyte, the density is optimized more towards anabolism. Whereas in a
00:08:25 very energy dense cell, like a muscle cell, where ATP is probably more important than precursor to
00:08:32 building blocks, you're optimizing around this other function of ATP generation. That's basically
00:08:36 where I was asking. On a first approximation, that's true. Although, because there's a third
00:08:41 function, that simple theory, I don't disagree with that. I just don't think about it anymore
00:08:48 in those simple terms because there's a third function that is becoming very dominant. And I
00:08:53 actually don't know this third function I'm going to talk about, how it fits into that paradigm
00:08:58 that you just explained. And that's why I've stopped thinking about more or less mitochondria.
00:09:03 And that third function is that mitochondria are constantly generating signals to the rest
00:09:08 of the cell.
00:09:10 These signals are optimized for cellular function.
00:09:14 What are these signals?
00:09:15 One of them is the electron transport chain is not a perfect system, and it leaks electrons.
00:09:22 It can leak a little bit of electrons or a lot of electrons to make H2O2, make superoxide
00:09:28 first and then H2O2.
00:09:29 People used to think H2O2, hydrogen peroxide in cells, damaging, damaging, damaging.
00:09:35 In fact, the oldest theory of aging says that as you get older, your mitochondria degenerate
00:09:41 and they make copious amounts of H2O2 to cause degeneration of the muscle, of the neuron.
00:09:48 I do want to just make sure people understand how that's happening and why it's happening.
00:09:52 I think a little bit of biochemistry won't kill someone.
00:09:54 So when acetyl-CoA is running through these four structures, these four complexes across
00:10:01 the electron transport chain...
00:10:03 It's not that.
00:10:04 Acetyl-CoA is part of the Krebs cycle.
00:10:06 Yeah, we can get into it.
00:10:07 Yeah, we can do a little biochemistry.
00:10:08 It's okay.
00:10:09 So you go from glucose to pyruvate.
00:10:11 Pyruvate comes in the mitochondria.
00:10:13 Pyruvate becomes acetyl-CoA along with oxaloacetate to jumpstart the TCA cycle.
00:10:19 Let's just look at that first stop.
00:10:20 the pyruvate to acetyl-CoA, it takes an NAD molecule and makes NADH. NADH is full of
00:10:28 electrons. It goes to complex I of the electron transport chain. Complex I takes that NADH to
00:10:36 electrons and makes NAD. The reason why people are so interested in NAD precursors is they're
00:10:42 thinking their complex I is not working so well because it's not giving back the NAD to make
00:10:47 mitochondria run to generate ATP in the TCA cycle. So if I give a lot of NAD, maybe I can overcome
00:10:54 the complex one deficit, which is found in Parkinson's, linked, and whether it's linked
00:10:59 to normal aging is debatable, and we'll get into that. And so that NADH electrons now are going to
00:11:04 go down the electron transport chain with the final acceptor of those electrons being oxygen.
00:11:10 The best analogy I can think of is a waterfall through a tube, and it's going through a tube
00:11:15 into a tank. The tank is the oxygen that's accepting all that water. There are holes,
00:11:20 very tiny little holes in that tube. That's that leak. And that leak can increase or decrease
00:11:27 depending on how filled that tank is. If the tank is completely full, all of that water backs up,
00:11:33 and now you get that leak happening because it has to go somewhere. So that's a simple way to
00:11:38 think about it. The best analogy I can think of is you have this NADH, which has these two
00:11:45 electrons and it passes it down the electron transport chain, keep it simple, and oxygen is
00:11:50 the final acceptor of it. This allows the NADH, when it passes those two electrons, it regenerates
00:11:56 NAD and it keeps the TCA cycle going. But that electron transport chain isn't perfect. Not every
00:12:03 electron always gets to oxygen. There's a little bit of imperfection, a little bit of leak, and
00:12:09 that one electron can take oxygen to something called superoxide, which becomes quickly converted
00:12:16 by some enzymes called superoxide dismutase to make H2O2. So what people thought is, well,
00:12:22 the electron transport chain, this slightly imperfect system becomes more imperfect. So
00:12:28 now it's leaking more electrons in neurodegeneration and cancer and everything. And now it's making
00:12:34 copious amounts of H2O2. And is there evidence, by the way, Nav, that even in an absent disease
00:12:39 state, as a person ages, as they go from 10 to 20 to 30 to 40 to 50 to 60, what we represent in
00:12:45 the textbook, which is the final output after you've transferred all of the electrons and made
00:12:51 all of the ATP, you have two outputs, carbon dioxide and water, which is what we are all
00:12:56 breathing out. Coupled to generating ATP. Yep. Is the idea that absent disease, just aging
00:13:04 increases the fraction of H2O2 relative to just H2O?
00:13:10 I don't think so.
00:13:11 Okay, interesting.
00:13:12 I wanted to go through this just so people understand
00:13:14 what H2O2 is relative to the normal process of H2O.
00:13:19 What you're asking me is, in a normal person, does the system become leaky?
00:13:24 Just by age.
00:13:25 Just by age. I don't think so.
00:13:27 This is one of the new paradigms.
00:13:30 it's not written in stone yet, but this is what we've been working on. Not only that,
00:13:35 but let's back off. To begin with, do we make copious amounts of H2O2 to levels that become
00:13:42 toxic? I don't think so. We have a lot of antioxidants, Peter, that keep that in check.
00:13:47 Explain to folks what an antioxidant is. We're taking it for granted as we say this.
00:13:51 Yeah, yeah, yeah. So it's a protein that can detoxify different molecules of reactive oxygen
00:13:56 species. So there's a family of proteins called superoxide dismutases. They take superoxide and
00:14:02 make H2O2. H2O2, when you make it, has three choices. First choice, which is, it almost happens,
00:14:10 is because we're full of proteins that degrade it to water. So there's two classes. One is catalase,
00:14:15 is the other one is peroxyredoxins. And we're full of, they really have high reactivity to it
00:14:21 and they convert it to H2O. I don't want people to lose the thread. H2O is a very stable molecule.
00:14:28 Very stable. Okay, so you have oxygen. It has these covalent bonds to hydrogen. Very stable.
00:14:34 You have a couple electrons that can create polarity, but why is it not reactive in a way
00:14:41 that H2O2 is reactive? Actually, H2O2 is not that reactive. Superoxide is super reactive,
00:14:48 but there are cysteines which can readily get oxidized by H2O2. And that's part of the second
00:14:55 thing that I was going to talk about, which is this cysteine on certain proteins. And we don't
00:15:00 quite know the code of that still. That changes is the activity of that protein, and that's all
00:15:05 signaling. That H2O2 with iron can undergo a fenton reaction to make hydroxyl radical,
00:15:12 doesn't last long, and it's super toxic. It'll react with anything that it touches.
00:15:18 That can, with a polyunsaturated fatty acid, can make something called lipid peroxide and start a
00:15:24 chain reaction, which is now called ferroptosis. It's a new form of cell death discovered about
00:15:29 12 years ago. So the more we create H2O2, the more we theoretically risk this process.
00:15:37 The ferroptosis process. Yes, exactly. So you make the H2O2, lots of proteins to get rid of it.
00:15:45 You always need a little bit, we think, for that signaling, that cysteine oxidation. But if you
00:15:51 overwhelm these antioxidants for whatever reason, for some reason, the antioxidant capacity goes
00:15:56 down, you start to push that not only for the signaling, but you start to push it towards this
00:16:01 ferroptosis. And when people hear antioxidant, they automatically, I would assume, think of
00:16:06 things that we eat that are known to have antioxidant properties, such as vitamin A or
00:16:10 vitamin E or vitamin C. So how much of an individual's antioxidant buffer capacity
00:16:17 is a function of how much antioxidant they consume? Or is that an overly simplistic way
00:16:23 to think of it? No, no, no. So the toxic ones that I'm talking about, the lipid peroxide. So
00:16:28 vitamin E is pretty good at that, detoxifying that. Okay. Probably the biggest one is selenium.
00:16:34 So the proteins that are responsible in our bodies to get rid of those lipid peroxides,
00:16:40 it's a battle, right?
00:16:41 You're making these hydrogen peroxide, you're making lipid peroxides, but we, most of us,
00:16:47 have enough of, for lack of a better word, antioxidant capacity, Peter, to keep those
00:16:53 levels in check.
00:16:55 So selenium, there are countries, by the way, which are a little bit selenium deficient.
00:17:01 Northern New Zealand, Sweden, Finland, the U.S. has a high selenium diet.
00:17:06 And that's based on the soil?
00:17:07 The soil.
00:17:08 So just to finish, selenium is required for the proper activity of proteins like GPX-4,
00:17:15 which get rid of those lipid peroxides.
00:17:17 Because it accepts electrons easily, or?
00:17:19 Selenium is part of the GPX-4.
00:17:21 The moiety.
00:17:22 The moiety to make it work.
00:17:23 But this is my point.
00:17:24 If you have a proper diet, you should have enough antioxidant capacity.
00:17:29 there are places that may be deficient on it. I just want to make one thing about vitamin C,
00:17:33 the granddaddy of them all, as they say. Vitamin C, and we're going to talk about going back to
00:17:38 my signaling, is a very important protein, not for its antioxidants, but as a cofactor
00:17:43 for a whole class of enzymes called the alpha-ketoglutarate dioxygenases. All the epigenetic
00:17:51 clock stuff that people like, this is run by these enzymes, and vitamin C is needed to make sure
00:17:56 those enzymes run. Two oranges a day is enough to make those enzymes run.
00:18:00 And so is it your point of view that all of the trials that have looked at supplementing
00:18:04 with antioxidants, they've all failed? Yes.
00:18:06 Proven no health benefits. Some cases worse with cancer?
00:18:09 Yes. Is your hypothesis for why that's the case that A, we have sufficient enough
00:18:17 antioxidants in the diet, so giving more doesn't really do anything? Is it B,
00:18:21 that we're not taking enough. So the antioxidant trials failed because they failed to give enough
00:18:27 and you would have to give really, really, really high doses to get the benefit. Or C,
00:18:32 actually they do work, but they're taking away the reactive oxygen species, which we need to
00:18:37 do something valuable or D, something else. A and C. In other words, most of us have enough.
00:18:42 I agree. Some countries may have low selenium, so they may want to take selenium in them.
00:18:47 There are people who don't eat enough oranges or have enough, they're not scurvy, but you know,
00:18:52 there's actually quite a large level of differences in vitamin C levels in people.
00:18:56 But generally, if you're eating a healthy diet, I think it's the A. The other part is that people
00:19:01 who are taking gobs of it might be interfering with the normal function. So remember, I said
00:19:06 something like H202 can become damaging if it becomes lipid peroxide, something like vitamin
00:19:12 and he can take care of that. But there's also this need to keep the cysteine oxidation,
00:19:17 what I call signaling. And my lab has really worked a lot on it. And we've done genetic
00:19:23 experiments where we decrease mitochondria's ability to make H2O2, for example. A T-cell,
00:19:30 when it sees a pathogen, will proliferate okay, but it won't make the memory T-cells.
00:19:34 So it actually hurts the T-cell.
00:19:36 It hurts the T-cell.
00:19:37 Hurts the immune cell.
00:19:38 Hurts the immune system.
00:19:39 Yeah, for functioning properly. And there are some data
00:19:42 like in sepsis trials, which have failed, in fact, made it worse. There's the antioxidant
00:19:47 trials in those cases. So I think we have enough, and sometimes it might interfere with normal
00:19:52 biology. And I think this is a paradigm shift. It used to be antioxidants, bad, bad, bad,
00:19:58 take antioxidants. It's a little nuanced. H2O2, good, within levels. If it becomes lipid peroxides,
00:20:05 they can be managed due to these selenium-dependent enzymes, bingo, that causes DNA damage.
00:20:12 and everything. All right. So let's go from function to dysfunction. Can we just go back
00:20:17 to function? Because I only talked about one of the H2O2. There's a lot of them. Let me just give
00:20:22 you two more, which are important for this discussion. The second one is metabolites.
00:20:27 So those TCA cycle metabolites that are linked to electron transport chain,
00:20:32 including acetyl-CoA you just mentioned, alpha-ketoglutarate. So it turns out that
00:20:37 protein acetylation, when proteins get accelerated at lysines, is a way to change their function.
00:20:44 A lot of the acetyl-CoA comes from mitochondria. So you could see how mitochondria controlling
00:20:49 acetyl-CoA levels. Probably one of the three most important things that drives autophagy is
00:20:54 acetylation of protein. Yeah, well, the big one is also in the histones being acetylated to keep
00:20:59 a chromatin open or closed. That mitochondria controls. So that's a signaling aspect of
00:21:04 mitochondria now. It has nothing to do with ATP. Alpha-ketoglutarate. So there's 75 enzymes called
00:21:10 the alpha-ketoglutarate dioxygenases. They use oxygen and alpha-ketoglutarate. They use iron,
00:21:17 Fe2+, and they make succinate. To recycle that iron, you need vitamin C to make them functional.
00:21:24 So when you don't have enough vitamin C, those enzymes aren't working. So let's just go through
00:21:29 those. So now again, you have alpha-ketoglutarate as an input from mitochondria into running 75,
00:21:36 I would argue, some of the most important enzymes. The enzymes that cause DNA methylation to be
00:21:41 DNA demethylation or alpha-ketoglutarate. Histone demethylases, the collagen prolyl
00:21:47 hydroxylases, you and I hopefully have good skin as we age, which are alpha-ketoglutarate
00:21:53 dioxygen. In fact, the vitamin C that people like to put on their skin, I always argue,
00:21:57 is because you keep the collagen prolyl hydroxylases from working properly.
00:22:03 So now you have, think about it, your DNA demethylation.
00:22:07 If your DNA is hypermethylated, you typically turn off genes.
00:22:11 The epigenetic clock phenomenon, and I think you've discussed a lot about
00:22:15 whether it's of any value or, you know, and I'm not going to debate that,
00:22:19 but all I'm going to say is that people who are so into their epigenetic clocks,
00:22:24 alpha-ketoglutarate is controlling those clocks.
00:22:27 because they're needed to keep the demethylase reactions going properly.
00:22:32 So that's our second major, major function.
00:22:34 Right. So you have H202, you have TCA cycle metabolites, controlling essentially epigenetics.
00:22:39 Your third one is, so mitochondria has its own DNA and RNA. If it spills out,
00:22:45 the same sensors that look at pathogens, we have things that say, I'm infected with a pathogen,
00:22:51 I have to turn on a cytokine. Well, the mitochondria is your bacteria. The current
00:22:56 bacteria of how we have a normal eukaryote is an archaea, which is not a bacteria, it's a kingdom
00:23:03 by itself, and an alpha proteobacteria. The two of them had a symbiosis, as before oxygen was around.
00:23:09 So there's a bacteria within us. And if that bacteria releases its DNA or its RNA, it's viewed
00:23:16 as a foreign, and the same inflammation pathways... I'm sorry, why is it that we didn't thymically...
00:23:21 Why were we not exposed to that? Basically, why did our thymus not account for that? Because there
00:23:26 must have been some disruption of mitochondria during embryogenesis. Great question. Actually,
00:23:31 I don't know the answer to that. One thing could be that some of those antigens are not presented.
00:23:37 They're not as easily presented because they're hidden and because they're in the mitochondrial
00:23:40 matrix. But the key point, just to sort of wrap this up, I mean, there's many other things that
00:23:46 mitochondria release, okay? And again, to the listeners, especially my colleagues,
00:23:51 as just in the interest of time for our discussions, we're going to keep at least
00:23:55 three of them. There's many more. One is H2O2, needed for immune function, needed for cell
00:24:01 differentiation. Alpha-ketoglutarate, which we want to talk about later in the supplement section,
00:24:07 and keeping the epigenetics going in a proper way. And lastly, sometimes mitochondrial DNA
00:24:14 or RNA being released is to turn on immune function. And again, like with immune function,
00:24:20 if it's chronically? You know, some people think it's not your ATP. Peter, you asked whether it's
00:24:26 decreasing with age or H2O2 increasing. Could it be we just have leaky DNA from mitochondria?
00:24:33 Why is that a good thing, Nav? Because... No, no, no. I'm not saying chronically
00:24:36 leaking is not a good thing. No, no. But I'm saying you mentioned earlier that if the
00:24:40 mitochondria releases its DNA and or RNA, it's going to activate the immune system because it's
00:24:45 not identified as self. But that activation of the immune system is very specific. So what is
00:24:51 it targeting besides the DNA and RNA of the mito? So there's two big questions in that field.
00:24:58 How it gets released? It's not known. It's not mitophagy or... People argue that improper
00:25:05 mitophagy might release it or the normal turnover, fission fusion. Where H202, we know how it's
00:25:11 released. Alpha-ketoglutarate has actual transporters. This one is a bit of a black box.
00:25:18 But once it's released, we know the target. C-gas sting, MAVs for the RNA. So there's
00:25:23 dedicated... And what do those T-cells go and do? Who do they turn their ire on once they're
00:25:28 activated? Right. Not only T-cells, but any cell can release it. And the signals they release are
00:25:33 type 1 interferons, which can then orchestrate the whole immune system. But I think the question
00:25:38 you're asking is, is this a regulated system? And is it for a net positive? In other words,
00:25:44 is this something we are doing to amplify an immune response? So if a virus comes in you,
00:25:49 if influenza comes along and attacks the endothelium or the epithelium rather of your
00:25:54 throat, is it also something that the mitochondria do say, how can I participate and help the
00:26:00 organism? I'm going to release RNA and DNA. It's going to make more interferon. It's going to make
00:26:04 more T cells, more B cells. Is that the theory? Absolutely. In fact, people have done those
00:26:09 studies. They've taken different viruses. I did one, helped a colleague in Northwestern where they
00:26:13 did pox viruses, good old pox viruses. And lo and behold, mitochondrial DNA gets released.
00:26:19 It used to turn on exactly what you're saying. What's the signal? How does it know to do that?
00:26:23 Yeah, exactly. So the mitochondrial DNA, if I had to compare H2O2 versus the DNA,
00:26:29 H202 is still a black box what it hits.
00:26:32 Which proteins, which cysteines?
00:26:34 We know how to manipulate.
00:26:35 Mitochondrial DNA, we know the receptors it's going to hit.
00:26:39 I don't think, people might argue, I don't think we have a good explanation how it gets out.
00:26:43 And if we knew if there was a select transport or something, then we can manipulate and maybe
00:26:48 even make drugs against it, depending on what you want to do.
00:26:51 But what I was going to get at is, you have this mitochondria with two membranes.
00:26:55 I could imagine, Peter, a scenario where you're making enough H2O2, you're making enough ATP,
00:27:03 you're making enough TCA cycle metabolites like alpha-ketoglutarate. So everything is great.
00:27:08 But you know what's not great is maybe the membranes are not perfect and they're leaking
00:27:14 a little bit of mitochondrial RNA or DNA. And by releasing a little bit of mitochondrial
00:27:19 RNA or DNA over 20, 30 years is causing a little bit of an immune response,
00:27:27 a little low-grade inflammation all the time. So some people think maybe the autoimmunity that
00:27:32 you get as you age or the inflama aging might be of leaky mitochondria. Not enough that it
00:27:39 compromises DNA, not that it compromises alpha-ketoglutarate or even my beloved H2O2
00:27:45 signaling, but it just sort of leaks out at low levels. And that's the increase in inflammation
00:27:51 that we're seeing. It's a hypothesis. It's difficult to test because exactly what you
00:27:57 pointed out, how does it get out? Because if I knew how it got out, I could then come in and stop
00:28:02 it in a mouse model or whatever and say, look, here's the aging, inflammation aging, and now
00:28:08 it's not happening. Do you know, Nav, that it gets out of a cell that remains? Or does getting
00:28:15 out imply that that particular mitochondria, that organelle was destructed and it's binary?
00:28:21 Anytime DNA and RNA get out, it means that particular organelle is gone versus this idea
00:28:26 of a leaky organelle. You hit it on the thing. We don't know that. Well, this is my problem with
00:28:32 the idea. I've always assumed, you know what, we forgot to, actually this is a perfect segue,
00:28:38 I forgot to mention the most important experiment done in signaling by Zhao Dong Wang, which got
00:28:43 people like me inspired in the mid-90s to think of H202 and other things, which was that he showed
00:28:49 that cytochrome C, which is part of the electron transport chain, part of electrons flowing,
00:28:54 making ATP, if it gets out from the mitochondria, that cell goes on to die. The mammalian death
00:29:01 signal is cytochrome C getting released. Now, there's something called where cytochrome C can
00:29:06 get a little released and the mitochondria can repair itself. Many people think the mitochondrial
00:29:11 DNA must be doing that. So in other words, it's not during cell death. When I first saw it, I was
00:29:16 like, the cell's about to die. It's just turning on inflammation, exactly on first principles. But
00:29:21 it looks like there's improper, maybe permeabilization or some leaky mechanism I don't
00:29:28 understand. And I actually struggle with it at how does it really work? Because to me, it would
00:29:32 seem binary, but people argue now that cytochrome C even, which is binary, that there is cytochrome
00:29:39 C a little bit gets released and then it can repair itself and it's turning on stress signaling. So
00:29:45 more to be discovered on that front. So let's put a bow on this because the two biggest and
00:29:51 most obvious things that the mitochondria does, which is generate ATP, anything that interrupts
00:29:57 that significantly is incompatible with organism life.
00:30:01 That's not true.
00:30:01 I mean, cyanide.
00:30:03 If you interrupt that process, we're done.
00:30:05 If you stop making ATP, you're dead, right?
00:30:07 That's what I mean.
00:30:07 So the cyanide one is an interesting one
00:30:10 because if you do these experiments genetically,
00:30:13 so cyanide binds to cytochrome oxidase
00:30:16 and sort of carbon monoxide and many other things.
00:30:18 But if we genetically, in a heart
00:30:21 or in a dopaminergic neuron, or even in a muscle,
00:30:25 three bioenergetically heavy things,
00:30:27 There are signaling pathways, such as activation of AMPK, which can turn down mTOR.
00:30:33 That cell lives fine for months and months and months, and it's on glycolysis.
00:30:39 So you're saying it's not that it evolves away around that particular complex within
00:30:44 the mitochondria.
00:30:45 That's very interesting.
00:30:47 Yeah.
00:30:47 Why is it?
00:30:48 And by the way, here's a crazy thing.
00:30:50 A colleague of mine at Northwestern knocked out components of the electron transport chain.
00:30:55 the heart continued to pump on glycolysis. For how long? Months. And then, but you know what
00:31:01 happened? All this signaling that I'm talking about, and he doesn't understand all of it,
00:31:05 but that signaling caused it to hypertrophy. And now it can't contract and the mouse dies.
00:31:09 But why is it then that cyanide is so lethal in seconds? Why can't the organism survive
00:31:15 on glycolysis for a while? I think because when we genetically do it,
00:31:20 and by the way, I actually don't know why which organ failed. So the ones that we've done,
00:31:25 We don't actually know. Same with rote known, which is a complex one inhibitor linked to
00:31:29 Parkinson's. So if we do the same experiment in dopaminergic neurons, those neurons basically
00:31:35 live off glycolysis for three months in a mouse, and then the neurons start to die.
00:31:40 But during those three months, they stopped making dopamine. So in other words,
00:31:43 they have enough energy to live, but not to be functional.
00:31:47 All right. I'll take my extreme statement back.
00:31:49 So it's not about death.
00:31:50 It's profound dysfunction.
00:31:51 But it's dysfunctional. But the question is, why is that dysfunctional?
00:31:55 Yeah. But clearly, top hierarchy function of mitochondria make ATP. Another big function of
00:32:02 mitochondria is make metabolic building blocks. And then the third one I'm calling 3A, 3B, 3C,
00:32:09 and those are the three things you just talked about. So that's the H2O2, that's the protein
00:32:13 acetylation and histone acetylation, all of the acetylation pathways. And then the third one,
00:32:17 which is, I mean, three, call it three C. The really radical sounding one is actually it's
00:32:22 to release genetic material to heighten immune response. Right. Right. Also the fourth one you
00:32:28 could argue is cell death. Cytochrome C release. When it gets released, that cell typically goes
00:32:34 on to die. Oh, it's the whole cell, not just that mitochondria. Oh, no, no, no. Cytochrome C turns
00:32:38 on caspases. It's the apoptosis signal. The apoptosis signal. Yeah. The dominant mammalian
00:32:45 apoptosis signal is when the cell gets neglected for whatever reason, it releases cytochrome C and
00:32:52 that cell goes on to die. Yeah, so mitochondrial cell death clearly is a big thing. And there's
00:32:58 many others as well. Your favorite, mTOR, when mitochondria, I think the reason in our experiments
00:33:05 they can survive the organism or the organelle, I mean, sorry, the cell can survive for long
00:33:10 periods of time, even though it's not functional because it's not making the signals or metabolites.
00:33:15 is that AMPK gets activated when mitochondria don't make enough ATP. And AMPK will tell mTOR
00:33:21 to shut down the anabolic processes. So it's just saying, let's hold on to the cell, live off
00:33:27 glycolysis. Yeah, we can't make all the building blocks or dopamine for a dopaminergic neuron.
00:33:32 But then there's some cells like the heart, it still starts to grow. It's crazy. We don't quite
00:33:37 understand all of this. But this is a new way to think about, I mean, for the listeners, I want
00:33:42 them to not only think about ATP as the hierarchy, not only the metabolites, but all of these
00:33:46 interesting communication of signaling. The nice thing about all these signals is if we know how
00:33:52 these signals are being released, maybe we can modify them in particular diseases.
00:33:58 So in a person listening to us or watching us who wants to know how well their mitochondria
00:34:04 function, what test can they do? I have my favorite, but I want to know yours.
00:34:09 Okay. I have none.
00:34:10 You have none?
00:34:10 I have none without taking a biopsy.
00:34:13 All right. Well, tell me if you do a biopsy, what you're going to do? What are you going to look at?
00:34:16 Where are you going to biopsy? The muscle?
00:34:18 Exactly.
00:34:19 Okay.
00:34:19 I don't know.
00:34:20 What assay can you do in the lab?
00:34:22 You can do metabolomics. That'll tell you your TCA cycle metabolites are up or down in a snapshot.
00:34:28 It's not perfect. You can take those and do isolated mitochondria and you can look at maximal
00:34:33 efficiency. I don't know how useful that is because here's the reason. What human genetics
00:34:39 has taught us from mitochondrial mutations, the people who have genetic mutations, either in their
00:34:44 DNA, their nuclear DNA or their mitochondrial DNA, which causes their proteins to be dysfunctional
00:34:50 in their mitochondria, you have to lose 70% of mitochondrial protein function. It's that redundant.
00:34:57 It is that much excess capacity. Makes sense. I mean, if you're going to have something that
00:35:02 is that critical to life. Right. So you and I started, let's say, at 100%. And you can go
00:35:07 all the way down to 70% and 80% in almost every tissue before-
00:35:11 20 to 30, you mean?
00:35:12 Yeah, yeah.
00:35:13 Yeah, yeah, yeah.
00:35:13 But 20 to 30, sorry, left.
00:35:14 Yeah, remaining.
00:35:15 That remaining.
00:35:15 So here's the analogy.
00:35:16 You're a car guy, remember?
00:35:18 So we're going to use the good old Aston Martin, because I like James Bond.
00:35:21 The last one in No Time to Die, I think in the last movie, that Aston Martin, I looked it up
00:35:26 yesterday, 217 miles an hour.
00:35:28 My favorite one, the classic 1964 James Bond, and the Goldfinger one goes about 140 miles an hour.
00:35:36 Now, you could look at those two and say, I don't want this one, man. This one's not.
00:35:40 In the city of Chicago, you can only drive 50. It's just not rate limiting. That's the best way
00:35:45 to think of it. So when you're measuring it, how do you figure out it's rate limiting?
00:35:48 Okay. Well, let me extend your car analogy then. I love that analogy. You're looking at one
00:35:53 parameter of the car, which is speed. Is speed in your analogy ATP production?
00:35:59 It is just the ability to maximally consume oxygen. That's the first one, by the way.
00:36:04 Yeah, yeah. So my question to build on your analogy is the newer Aston Martin doesn't only
00:36:09 go faster. It's more fuel efficient. It has better suspension. It handles better. The transmission is
00:36:15 infinitely better and smoother, et cetera, et cetera. Can you infer from function one, remember,
00:36:21 I'm going to talk about these now as function one, two, three A, three B, three C, et cetera.
00:36:24 Can you infer from function one, the capacity of two and three?
00:36:29 You can, number two, because what you can do in an isolated mitochondria is you can just feed it
00:36:36 all sorts of carbons, fatty acids, pyruvate, whatever you want, and ask how fast it can run
00:36:41 at top speed. But then you can also give it ADP and ask it how well it can make ADP. That's that
00:36:49 fuel efficiency. So we can definitely do those two things. And there are people, and then also
00:36:54 So you can measure its ability to generate H2O2.
00:36:58 But we have no idea what that tells us about its ability to control the immune system or
00:37:05 these other much more nuanced ideas.
00:37:07 Right, right.
00:37:07 And then there are parameters like their metabolite pyruvate ratio, beta-hydroxybutyrate,
00:37:14 aceto-L.
00:37:14 That's an NADH, NAD surrogate that people use in patients with mitochondrial mutations.
00:37:19 Those levels, they have to be quite high.
00:37:21 hey, when a normal person, you're not going to, I mean, then there's something wrong.
00:37:25 There's medically something wrong. So you're talking about something as a canary in the
00:37:30 coal mine kind of thing. So here is my test. Here is my favorite way to determine mitochondrial
00:37:34 function. And it's purely focused on the first one. It is oxygen and ATP. You put a person on
00:37:42 a bike or a treadmill or something like that, and you see how much work they can do in watts or
00:37:48 METs while keeping lactate below 2 millimole. Because as long as lactate is below 2 millimole
00:37:56 in steady state, this person is maximizing mitochondrial capacity. Once lactate starts to
00:38:04 rise, you know that they have hit that threshold and now they are shunting through glycolysis.
00:38:09 So the difference between me and Tadej Pogacar, who's the greatest cyclist in the world,
00:38:14 It was actually just an article that came out in a medical journal very recently that
00:38:19 looked at the fact that his VO2 max they predict is the highest of any professional cyclist
00:38:26 ever and his ability, he can maintain seven Watts of output per kilogram longer than any
00:38:32 cyclist they believe has ever been able to do so.
00:38:35 So if you put me and Pogacar on a side to side ergometer and we tested this, once I
00:38:40 hit about 230 watts, my lactate's going to start going up. I can't keep it below two.
00:38:47 Pogacar is going to get to 350 watts. And if you normalize that for body weight,
00:38:52 it's even more profound. He therefore has much healthier mitochondria than me. Would you agree?
00:38:59 More efficient? Well, again, I haven't thought about sports medicine as much as you have. So
00:39:05 I'm going to ask you the question back. My understanding is that it's not only the
00:39:11 mitochondria efficiency, but the delivery of oxygen by the vascular, that's the other determinant.
00:39:18 100%. But at that point, neither of us are rate limited by oxygen delivery.
00:39:23 How do you know that?
00:39:23 I know that because we're only at about 60 to 70% of VO2 max when we're at that state.
00:39:31 So in other words, we're still well inside the envelope of what the cardiac output is
00:39:35 determining. By the time cardiac output is limiting you, you are generally in a glycolytic
00:39:40 state. Okay. So just to be, also for the listeners and for my own, there is the heart,
00:39:47 there is a blood flow. So those are two inputs in the system. And the third one is how efficient
00:39:51 mitochondria is using that oxygen to make ATP, to keep you going so you don't use your phosphocreatine
00:39:57 and glycolysis or lactate goes up. Those are the three inputs. And you're saying
00:40:01 that you're measuring this at a time when you're at least confident that you're not you and this
00:40:08 great cyclist. And anyone, truthfully. Or anyone, let's say, is not limited, rate limited by
00:40:13 the contraction as well as the delivery, and it's simply the mitochondria. Then I buy that.
00:40:19 We do this test on all of our patients. I've never seen a case where a person's what's called LT1,
00:40:25 lactate threshold one, which is about this zone two, is not in the vicinity of 60 to 70% of
00:40:32 ventilation max. Now, there are other components going on, and I want to be thoughtful about it.
00:40:38 We're not going to go down the rabbit hole too much on this, but of course, the amount of type
00:40:41 one muscle fiber a person has is going to play a role. There are other factors, but I guess my
00:40:45 point, Nav, is this strikes me as a really good poor man's test for mitochondrial function. You
00:40:51 You can't do this without healthy mitochondria and you can't do what Pogacar does without very
00:40:56 healthy mitochondria. But let's go back to my bond analogy. As I age, do I need to have fuel
00:41:03 efficiency, all of that, even like the James Bond 1964 car? Probably not. It depends on how much
00:41:09 physiologic reserve you want to have. Because at some point, I mean, using VO2 max as an analogy,
00:41:14 let's assume I measured your VO2 max today and it was 42. I don't have a nomogram in front of me,
00:41:18 but that would put you in the top quartile for your age. That number is going down at about 10%
00:41:24 per decade. Now there is a point beneath which, meaning there was a VO2 max point that once you
00:41:32 go below that, it impacts daily living. Now that depends on what you define daily living as.
00:41:38 For Peter Atiyah, that number is about 28 to 30. Once my VO2 max falls below 28 to 30 milliliters
00:41:46 per kilogram per day, my quality of life will suffer dramatically. For some people, that number
00:41:51 is 20, but for virtually every human on this planet who wants to live independently, that
00:41:56 number is about 15 or 16. So the argument I would have is everybody should have as high a VO2 max
00:42:03 as possible to give them as much optionality as possible in the inevitable state of decline. And
00:42:09 I think that is true for mitochondrial function. Two points. Going back to the car analogy,
00:42:15 you should be able to go 45, 50 miles an hour. If you have a car that's below that,
00:42:19 that's not a functional car, even in the city of Chicago.
00:42:22 Well, not only that, you don't want to be at the red line going 45 to 50 miles per hour.
00:42:26 You don't want to be at the red line to begin with, because it's going to go down to 20.
00:42:29 Violent agreement on that, okay? My point is, I am not convinced whether mitochondria
00:42:35 to go 200 miles an hour, yes, but whether mitochondrial function
00:42:41 becomes rate limiting. I agree with you. I don't know that.
00:42:43 I don't know that. So you made the analogy, you can go 100 miles, but we want you to go 200 miles
00:42:49 now. And guess what? We're going to boost your mitochondria to do that. Fair enough. And I'm like,
00:42:53 you know what, Peter, I'm happy. I just need to maintain 100 because I'm going to have a fall in
00:42:57 it. But even that fall that happens, is that really because of mitochondria or is it because
00:43:02 of neuromuscular? Totally agree. And that to me is the exciting question because I think on some
00:43:07 areas, I think when it comes to maximum aerobic output, I think the data look pretty clear that
00:43:13 it's actually cardiac output that becomes limiting, which means it is heart rate and
00:43:19 stroke volume and contractility. Those are going to be your limit at max output. When that escalator
00:43:25 is broken and you're late for your flight and you have to carry a suitcase that's 27 pounds
00:43:31 and sprint up three escalators, that is going to come down to cardiac output.
00:43:36 But when it comes to more sustained aerobic efficient activity, yeah, I don't know how much
00:43:42 of it is cardiac output versus mitochondria, et cetera. And the reason I think that the
00:43:47 mitochondrial topic is so interesting is because of how frequently it is implicated in metabolic
00:43:52 disease. And that's why your life's work is a very interesting topic. And we're going to talk
00:43:58 about things like all of the potential targets, including drugs like metformin. So I don't want
00:44:02 to spend too much time on the theoretical, but I want to set the stage for people. Why is this
00:44:06 such a fascinating question? I like this VO2 discussion because we're working on exercise
00:44:10 now to finally, I think, probably have to thank you for that. And just muscle health in general
00:44:17 to ask this question. But what I would say is, yes, could we find therapies to boost our
00:44:23 mitochondria so we look like that cyclist? So Peter can maybe take a supplement or something
00:44:28 or a drug that helps increase that efficiency. I just want your opinion on this. All I'm arguing
00:44:33 is as we normally age, does the mitochondria become limiting for daily activities or even
00:44:41 mild exercise to have a good quality of life? I am not convinced of the latter. Because other
00:44:46 things like what you said about stroke volume, oxygen delivery, you know, take your statins
00:44:51 or you don't have atherosclerosis. You got good pipes giving you oxygen. That's important.
00:44:56 And I think there's a component to this, which is it depends on the individual. So there was a
00:44:59 study that came out somewhat recently that looked at VO2max limitation in unfit and untrained
00:45:05 individuals. So it was a longitudinal study that followed unfit, untrained, non-exercising
00:45:11 population. And in those individuals, VO2max turned out to be more limited by peripheral
00:45:17 oxygen transfer. And you might look at that and go, oh my God, that's really interesting.
00:45:22 But then when you read the fine print, you realize that doesn't apply to anybody who's
00:45:25 exercising or training. Once you start pushing the envelope a little bit, cardiac output becomes
00:45:30 rate limiting. And so I do wonder if on the mitochondrial function side, it also may have
00:45:36 implications under, well, if you have a disease, if you have one of these many diseases that
00:45:41 directly implicates the mitochondria, the answer is this. If you are a very healthy, active person,
00:45:46 the answer is this. And if you were a sedentary person, the answer is that. We have to figure out
00:45:50 all those things. Yeah, I mean, we can both agree the three inputs in the system,
00:45:54 the heart stroke volume, how much is pumping, the blood going to the right place and mitochondria
00:45:59 extracting it. And it could be in three different population, you have three different problems.
00:46:05 By the way, I should be a little more accurate. When I say cardiac output, I'm including hemoglobin
00:46:09 in there. It's really oxygen delivery. So if you have a high cardiac output, but a low hemoglobin,
00:46:13 it's all for naught. But yeah, yeah, yeah. I like what you just said here. We could have
00:46:17 three different populations. And what's limiting is the delivery, but not the mitochondria or the
00:46:22 mitochondria extraction, but not the delivery. Let's pivot and now talk a little bit about
00:46:27 dysfunction. And let's talk about it in the broadest sense we can, which is, do we believe
00:46:33 that mitochondrial dysfunction is an inevitable consequence of aging, given that it is designated
00:46:39 as one of the OG hallmarks of aging.
00:46:43 Yes, I am skeptical.
00:46:47 A few times I'm going to bring up conflict of interest.
00:46:50 I think it's important to say your conflict of interest.
00:46:53 It is almost a conflict of interest for me to say that.
00:46:56 If I want to make a living, I should tell people mitochondrial dysfunction is why you're
00:47:01 aging, and lots of people do.
00:47:03 I'm not so sure.
00:47:05 Again, not in a diseased person.
00:47:07 We can talk about the disease.
00:47:08 We're talking about a normal, healthy person.
00:47:10 Let's talk about you and I.
00:47:11 We're old men now, relatively speaking.
00:47:13 We're 10 years older than when we first met, okay?
00:47:18 I agree.
00:47:19 The question is, going back to this analogy, if you have to go to 70, 80% of your efficient
00:47:25 mitochondria for it to have a cell not work properly, do you ever get to that?
00:47:31 The hallmarks, by the way, they're instructive, but they're misleading, all the hallmarks.
00:47:36 they are what's called a sufficiency experiment. What does that mean? That means if I take a
00:47:42 mitochondria and I perturb it, so healthy mitochondria is this high and I make it here
00:47:48 in a particular organ or an organism, it will degenerate and maybe it'll age or look like
00:47:54 aging. You could do it with a lysosome. You can make lots of cells senescent, but that doesn't
00:47:59 mean that normal aging, that's what happens. In other words, is mitochondrial dysfunction
00:48:04 necessary for normal aging. And it might be sufficient. So people have done what's a
00:48:10 sufficiency experiment, which is they take mitochondrial DNA and they cause mutations in
00:48:15 them genetically. So the mouse gets mutations only in their mitochondrial genome. People have
00:48:21 done it with the nuclear genome. And both of them age. I can tell you the new nuclear genome
00:48:27 mutations looks more like normal aging. Mitochondrial ones that they've generated,
00:48:34 in normal aging, we'll have this much mitochondrial mutations, let's say.
00:48:37 You have to go almost 10-fold higher mutations in order to start to see that organism degenerate
00:48:44 in a mouse. And it doesn't even look like a normal aging.
00:48:48 So let me make sure I understand that and replay it back to our listeners.
00:48:51 We're talking about something that we're taking for granted. I'll just state it quickly.
00:48:55 we have two genomes. We have a genome within the nucleus. That's the one we are almost always
00:48:59 thinking about. But then the mitochondria have their own DNA. We should just make sure everyone
00:49:03 understands that. Okay. If you take the DNA in the cell, what we're calling the nuclear genome,
00:49:09 and you apply mutations to it, because as we age, we are acquiring mutations,
00:49:14 you're saying you're able to replicate an aging phenotype by adding mutations to the nuclear
00:49:19 genome. Not me. This is the work of others in the field. Let me be very clear. None of this.
00:49:23 The field is, yeah.
00:49:24 Yeah, they've got some mouse models where you have some nuclear DNA mutations at the
00:49:29 same level as a normal-aged mouse would, and they have hallmarks of aging in that mouse
00:49:35 somewhat.
00:49:36 Conversely, when you take the mitochondrial DNA, not you again, but when the field takes
00:49:42 mitochondrial DNA and they insert mutations...
00:49:46 And let the mouse age.
00:49:47 And let the mouse age.
00:49:48 they do not see the same aging phenotype, even when they make those mutations at a rate of 10x
00:49:55 what occurs normally. Right. So normally you'll have this much mitochondrial mutations. If you
00:50:00 make a mouse as early in life that has the same amount, nothing happens, nothing happens. And then
00:50:04 you get to this huge threshold, boom, you start to see this mouse degenerate. Some of it looks like
00:50:10 aging, like hair loss, for example, but some of it doesn't. And some of the pathways that get
00:50:16 deactivated. So we took a cell recently called the microglia, which is a very important cell
00:50:22 for inflammation for lots of things in the brain. If you knock out mitochondrial function in that
00:50:28 microglia, at one ear, it doesn't look like an aged mouse. What if the dysfunction of mitochondria
00:50:36 does not come through genetic mutation? What if it comes through proteomic degradation? What if it
00:50:43 comes through membrane permeability? What if it comes through anything that is downstream
00:50:48 of transcription? What if it's a translational problem?
00:50:53 Just to back off, the reason we went through what mitochondria functionally do is you can now go back
00:51:00 and your three hierarchy thing. Do you lose ATP capacity as we age, mitochondria? Probably not.
00:51:07 Do we lose the TCA cycle, maybe not making enough metabolites?
00:51:12 Likely not.
00:51:13 Do we lose some of the signaling?
00:51:16 So in other words, instead of making too much H2O2, maybe we're not making enough in a certain immune cell.
00:51:22 Or we went through this whole, how is mitochondrial DNA might be leaky?
00:51:26 If it is leaky, you're not going to pick it up in the first two parameters of ATP, TCA cycle.
00:51:32 It's a different thing that's happening.
00:51:34 So I would define if mitochondrial dysfunction is related to aging, it isn't simply about
00:51:40 running out of ATP or running out of metabolites.
00:51:43 It could be this miscommunication.
00:51:46 It's not the glib, obvious first and second order deficiency that probably gets us into
00:51:51 trouble.
00:51:52 It's one of these fourth order terms that is much more nuanced at a cellular level.
00:51:57 And we're trying to figure that out.
00:51:59 We're trying to figure that out.
00:52:00 So I can tell you, when we take mice and we genetically don't let them make H2O2 enough,
00:52:07 their immune cells don't work, for example.
00:52:09 They don't differentiate properly.
00:52:11 Now, does that happen as we age?
00:52:13 Our ability to regenerate and all of that doesn't work as well.
00:52:16 Is that because we're not making enough H2O2 for mitochondria or something else?
00:52:19 It's an open-ended question, but I'm examining mitochondrial dysfunction,
00:52:25 not the lens of ATP, not the lens of just making metabolites for growth
00:52:29 that maybe not enough. For example, alpha-ketoglutarate levels go down as we age.
00:52:34 So is that somehow causing problems for DNA methylation, which could cause, obviously,
00:52:40 age-related defects? So there are so many compounds I want to talk with you about.
00:52:45 Can we turn to metformin as the starting place? Yeah. Okay. So you're one of the people who knows
00:52:51 more about metformin than almost anybody. Listeners of this podcast have heard me talk
00:52:55 about metformin quite a bit. I've done many podcasts on it. I've had near barzillion at
00:52:59 least twice. I've also been on Andrew Huberman's podcast where I did a very, very thorough journal
00:53:05 club looking at both the Bannister paper and the Keyes paper, which were really the two
00:53:10 massive epidemiologic studies. The Bannister paper was the one that really got people excited about
00:53:16 metformin as a gyroprotective agent. This is the study that looked at a cohort of the population
00:53:22 and made an observation that non-diabetic people not taking metformin had worse outcomes than
00:53:29 diabetic people taking metformin when it came to cancer. That basically got the idea going that
00:53:35 metformin could be protective of cancer. Roughly eight years later, a more, in my opinion,
00:53:42 rigorous study came out that challenged those findings, ran the analysis two ways with and
00:53:48 without a statistical tool used by the first analysis. And it didn't find that at all. And
00:53:53 truthfully, I found the second study more convincing. That doesn't mean metformin doesn't
00:53:58 work. It just means that the epidemiologic argument was more shaky.
00:54:03 What about the phase three clinical trial in breast cancer that failed?
00:54:06 Yeah. And then the prostate cancer trial. Let's talk about them.
00:54:09 But I agree with what you just said, by the way.
00:54:10 Yeah. So people have heard of metformin. I don't think there's anybody listening to us that hasn't,
00:54:15 But I don't think a lot of people maybe understand the complexity of that drug and how many different
00:54:19 things it does.
00:54:20 So can you explain to people how metformin works?
00:54:21 Yeah.
00:54:22 Well, again, working progress.
00:54:24 To the best of our knowledge.
00:54:25 Yeah, yeah.
00:54:26 I think you and I have talked about this before.
00:54:28 Let's just talk about any of the supplements we'll go through or any of the drugs.
00:54:32 Most of them you take oral.
00:54:33 Let's stick with that.
00:54:34 The first pass is the gut.
00:54:35 So with metformin, it goes in the gut.
00:54:38 And people have done this with C11 PET imaging.
00:54:41 they can see the gut light up, the intestines, the colon light up. Then it goes through the portal
00:54:46 vein to the liver. Then it goes, there's the kidney, and then it gets excreted out in a couple
00:54:51 of hours. It doesn't get in the brain. It doesn't get in the heart. It doesn't get in the muscle
00:54:56 at appreciable levels. Why is that? Because metformin needs a transporter, the organic
00:55:02 cation transporters. There's one, two, and three. There's some other ones as well, but let's just
00:55:07 keep it simple. The gut ends up taking it up quickly, but releasing it in the portal vein
00:55:13 slowly. So the highest concentration of metformin up to a millimolar, wow, is in the gut. By the
00:55:20 time it gets to the liver, it's less, 50 micromolar, 100 micromolar max. By the time it's in the blood,
00:55:27 10 micromolar. We have seen some immune cells, macrophages and T-cells, certain types,
00:55:32 and other people have noticed that they will also take it up. That you can't have the resolution
00:55:37 when you do a PET imaging analysis. But this part is really key, and it's going to explain
00:55:42 the cancer data in a second as well. You need the transporters. So the highest concentration
00:55:47 is in the gut. The other thing is... And everything after the gut. So when the gut
00:55:52 absorbs, so the gut has the transporter, obviously, but does it otherwise diffuse
00:55:57 into the portal circulation, or does it also require the transporter in the portal circulation?
00:56:02 It requires it to take it up. It needs a transporter to dump it out of the enterocyte.
00:56:08 So the metformin gets accumulated in the intestine or the colon cells,
00:56:13 but it takes a little bit longer, less transporters to release it into the portal vein.
00:56:18 Because that's a huge drop. To go from one millimole to 50 micromole is a 20x drop.
00:56:24 It's estimated as high as one millimole, but there is a huge drop in it.
00:56:28 Here's the experiment that got me super excited about why the gut.
00:56:31 So the original idea was metformin goes in the liver.
00:56:34 it decreases hepatic glucose production. So your liver, as you pointed out earlier,
00:56:40 can make glucose. It's largely an anabolic organ. And so what people, the oncologists have known
00:56:46 this, and you probably remember this, that if you take metformin and God forbid you have cancer,
00:56:51 they tell you to get off it because they use an FDG PET, a glucose tracer that they can easily
00:56:57 see that lights up. Well, if you take metformin and you give that glucose tracer, guess where
00:57:02 it lights up? One place, the gut. So why would it light up in the gut so much? A, it's at a very
00:57:08 high level. So every cell which has a mitochondria, if I inhibit the electron transport chain,
00:57:15 the thing that's generating ATP and consuming oxygen, to compensate for it, it takes up glucose
00:57:20 and goes through glycolysis to make the ATP deficit. So if you have a mitochondrial toxin,
00:57:26 the only way you survive is by sucking up as much glucose, running it through glycolysis,
00:57:33 making lactate, anaerobic fermentation. So why would that happen? Well, about 25 years ago,
00:57:39 biochemists noticed metformin can inhibit mitochondrial complex one. So this is a complex
00:57:45 one that takes the NADH and makes NAD to keep the TCA cycle and does a lot of other signaling
00:57:51 functions. So metformin, this is interesting, at least in that tissue, might decrease mitochondrial
00:57:58 NAD levels and increase mitochondrial NADH levels, the opposite of what NR is doing or the NAD
00:58:05 supplements. Or what people want NR to do. People want NR to do. And so Colleen Rezek in my lab,
00:58:10 I want to give some shout outs here, and Zach Zeebo, who's been doing the recent work on it,
00:58:15 Colleen made a mouse where she took a yeast protein from yeast.
00:58:20 Mammalian mitochondrial complex one is 45 subunits.
00:58:24 Some are nuclear encoded genes, products.
00:58:26 Some are mitochondrial.
00:58:27 It's the largest complex.
00:58:29 It looks like a boot.
00:58:31 Okay, it's huge.
00:58:32 The yeast has a single protein which can work as a homodimer.
00:58:36 The same protein comes together and it could do the same function as a mitochondrial complex one.
00:58:41 In other words, take NADH to NAD, pass electrons to the rest of the transport.
00:58:48 So there's some things it cannot do, but let's leave that aside.
00:58:51 But basically, it's a bypass.
00:58:53 So if you get rid of mitochondrial complex one, in many cases, this yeast protein can
00:58:59 overcome its loss.
00:59:00 So we've done this in dopaminergic neurons.
00:59:02 We lose complex one, and genetically, we put this protein, it's called NDI1, guess what?
00:59:08 The neurons are fine again.
00:59:09 So she made a whole mouse, which expresses the mammalian complex one and the NDI-1.
00:59:16 And she just asked, if I give metformin, what happens?
00:59:20 Metformin typically lowers the glucose levels.
00:59:22 If NDI-1 is there, it's largely refractory, arguing that complex one is the target.
00:59:29 And do we think that the majority of this is happening in hepatocytes?
00:59:33 Well, she did a whole body.
00:59:35 So Zach said, well, the largest place it's going is in the gut.
00:59:39 Let's start with the gut. Why the liver? So he takes the same NDI-1. He puts it only in the gut.
00:59:45 Nowhere else. First, he looks at that FDG PET scan. And in a mouse, it's huge with metformin,
00:59:51 completely abrogated. So that implies that metformin must be inhibiting complex one
00:59:57 because NDI-1 cannot be inhibited by complex one. So a normal mouse will have all this glucose
01:00:02 uptake in the gut. But if you have the yeast complex one, which is refractory to metformin,
01:00:08 Bingo, it goes down. And so what he noticed is people have seen GDF-15 goes up with metformin.
01:00:15 I don't know if you know that. So GDF-15, it tells you not to eat. It's an appetite suppressing.
01:00:21 Not at high levels. GLP-1 goes up, all from the gut. There's one called LAC-FE,
01:00:27 lactate and phenylalanine. All of these abrogated. We haven't done the, Colleen's doing the liver
01:00:33 experiment to see how much the liver contributes. By the way, our paper, the second one, I just
01:00:38 talked about the intestine. It's a preprint that anyone can see. We'll link to it, yeah.
01:00:42 But I'll tell you something that Zach noticed, which I think I give him a lot of credit for
01:00:47 here. He was looking at metabolomics of people in metformin. Do you know what the number one
01:00:51 metabolite goes down when people are on metformin? Citrulline. Citrulline, and the sports junkies
01:00:57 know this, citrulline is taken up, goes in the kidney, becomes arginine, and then the arginine
01:01:03 can be used by the rest of the body for nitric oxide and keeping you vasodilated.
01:01:08 So you can either absorb citrulline or you can make citrulline. Citrulline you make from ornithine,
01:01:15 which requires mitochondrial ATP. So what he found is that in the intestine, when mitochondrial
01:01:22 complex was being inhibited, those intestinal cells didn't make enough ATP and citrulline
01:01:29 levels dropped in the blood. The NDI1, the citrine levels didn't drop. Why am I making a big deal of
01:01:36 citrulline? Because there is a study out there which argues that you should take metformin while
01:01:41 you eat, and we'll get into it in a second, but long-term metformin use might compromise the
01:01:47 exercise-induced VO2 max. And hypertrophy. And potentially hypertrophy. I would argue that maybe
01:01:53 it might be because of the citrulline. It doesn't get into the muscle, but I can imagine lowering
01:01:58 your citrulline. So I just wonder. So you're saying if you're taking metformin, without it,
01:02:03 what it might be doing is inhibiting vasodilation, which inhibits the delivery of oxygen and or
01:02:10 alter other nutrients that are necessary for anabolism. The other one is B12. So B12 levels
01:02:16 go down with metformin. So people should take B12. People don't quite understand why, but the idea is
01:02:21 that the gut doesn't absorb it as well. But it's amazing, Peter, if you think about metformin,
01:02:27 when you and I started talking about it. We talked a lot about the liver effects,
01:02:31 but the gut, I mean, whether it's the citrulline effect, whether it's the B12 effect, oh, I didn't
01:02:36 even say. People on metformin have a very positive microbiome. The monosophilia microbiome, again,
01:02:42 I'm not a microbiome, but it's always positive. Whatever the good microbiome is, metformin gives
01:02:47 you that. Again, a gut effect. Now, how does that work? I don't know. But my point is the gut seems
01:02:52 to be a central player now. By the way, what happens when you give people intravenous metformin?
01:02:57 Where does it get taken up? Liver. More so in the liver. Not in the gut at all because the gut's not
01:03:02 going to see it. It's not going to see as much of it. It gets more liver. And by the way, you know,
01:03:06 the new metformin, the delayed release one, hangs out in the gut even longer. Does the muscle take
01:03:11 it up with intravenous? I don't know that. So that would suggest, assuming it does not,
01:03:15 it would suggest that any negative impacts of metformin on exercise performance probably are
01:03:21 circulatory, or they're basically coming from some metabolite upstream.
01:03:24 Right. And I'm going to argue maybe B12, because if you have B12 deficiency, you make something
01:03:29 called methylmalonic acid, which can be a complex 2 inhibitor in the mitochondria. I'm not saying
01:03:34 that's the mechanism, but I'm thinking exactly what you are, that it's got to be something
01:03:38 circulating. Most of it's in the gut, some in the kidney and the liver. Something from those organs
01:03:42 is affecting. I don't think this idea, oh, you have a complex 1 inhibitor now in the muscle,
01:03:47 and that's why you're VO2. And by the way, the data on the VO2 max, and you should
01:03:51 look at it yourself carefully, it's not like it completely abolishes it. And it's a short-term
01:03:56 study. To me, the really important question is, are there geroprotective benefits to metformin?
01:04:02 Let's examine the state of the science on that. Right. So if you take metformin at the time
01:04:09 you're having a meal, and we've seen this in our experiments, the postprandial, after eating a meal,
01:04:15 you have a glucose spike. I'm sure people with glucose monitors can see that spike,
01:04:19 and depends on what kind of meal. Metformin abrogates that. And that's, again, complex one
01:04:24 dependent. So there's pretty good data to suggest that all-cause mortality is somewhat linked to
01:04:31 those spikes. I mean, there's some studies out there. But acarbose does the same thing. Yes,
01:04:36 it does. And acarbose did extend life in the ITP. Richard Miller's wrong. But metformin did not.
01:04:44 both were delivered in the chow. So why do you think acarbose, which clearly does that,
01:04:50 and metformin, which might do that, didn't work? I don't have a good explanation to it. Not that
01:04:54 that was being measured, right? They didn't have glucose monitors. But I would argue that
01:04:59 now that we can clearly see this glucose spike happening, lots of people observe,
01:05:04 and metformin can abrogate it. I wonder if that's a good tool for people to use.
01:05:08 I don't know what you think of that. I'm just thinking aloud. You have a glucose monitor,
01:05:12 or you do it for three months, you get a good, good increase, decrease, you get some idea.
01:05:17 Well, I mean, I think, so look, there were three glucose regulating drugs that went into the ITP.
01:05:23 There's canagaflozin, acarbose, and metformin. The way the ITP is designed, the drug is always
01:05:29 in the food. So the vehicle of delivery is always the same. Canagaflozin and acarbose worked.
01:05:37 Not many drugs work in the ITV, but those two did, and metformin did not.
01:05:41 And so what do you think explains that difference?
01:05:44 I don't have a good explanation for that.
01:05:46 The canna drug, some people argue, is a complex one inhibitor too, by the way.
01:05:50 In addition to being an SGLT2 inhibitor.
01:05:51 Yeah, there's some papers on it, and I think it would be good for us to run those through
01:05:55 our NDI1.
01:05:57 I don't have a good explanation for the mice.
01:05:58 All I'm just saying is that in humans, that glucose spike can be reduced by metformin.
01:06:04 I think you would agree with that.
01:06:05 People should do that study carefully. They're small studies. Anyone can do it who's on a glucose
01:06:11 meter who's taking metformin. And anecdotally, when I ask people, they go, yeah, yeah, when I
01:06:15 take metformin before a meal, that's the key. How long before? 30 minutes before a meal,
01:06:20 probably. Within 30 minutes, it's in the gut. And the data on the pre-diabetes people,
01:06:26 metformin is much better than the full-blown diabetes. It always has been. If you're on full
01:06:31 diabetes, we know the Gs, GLP-1, the triple G that'll come, yeah, and the SGL-2. So you and I
01:06:38 would both agree it has some beneficial effect in keeping your glucose learning, right?
01:06:42 I completely agree with that.
01:06:43 Okay, because I'm going to go through the four horsemen now.
01:06:45 Yeah, and I think that metformin should always be considered a first-line drug in people who
01:06:50 are pre-diabetic or very insulin-resistant. But the real question is, should a person who's
01:06:55 insulin-sensitive consider taking it for these geroprotective purposes?
01:07:00 Right. So I'm going to just argue that you get a better microbiome and you get a better glucose
01:07:07 lowering if you're on metformin. I will accept the second. I will plead ignorance on the first
01:07:13 because I don't know what a better microbiome means. There are these microbiome community
01:07:18 that say this is a good... I don't know. These are the same people who tell you that the microbiome
01:07:23 is 10 to 1, your normal cells, and blah, blah, blah. And all of that stuff has been proven to
01:07:26 me wrong. I know. I'm not, that is not the reason to do it. I'm just saying, and because it's in
01:07:31 the gut, I always get people saying the whole thing is in the gut now. Is it going to make
01:07:35 my gut leaky? What I'm saying is whatever that is, it's not affecting that in a negative way.
01:07:41 I'm going to assign very low confidence to that point because I think that is still very,
01:07:46 very foggy. But the second point is true. It lowers blood glucose. Okay.
01:07:50 But you have to understand, Peter, if I'm going to talk about the gut,
01:07:53 these days, the large public is dying to know, will it give me a bad microbiome?
01:07:58 I want to make sure we're not feeding into...
01:08:00 Yeah, I don't want to feed into the scientific illiteracy that has become the way we talk
01:08:06 about the gut. Good versus bad. Like good cholesterol versus bad cholesterol. People
01:08:11 still say that it is a meaningless concept. There are microbes that generate butyrate,
01:08:15 which has been shown mechanistically to be good. Those microbes are increased when you
01:08:20 take metformin, so put it that way. But the second thing is cancer, which is where you started. So
01:08:26 it's failed. We can both agree on that. On clinical trials, there's always some signal here. So the
01:08:32 prostate one, and there was a subset of patients that it looked pretty good. But generally, let's
01:08:37 just say it's a negative. So why is it a negative? So we did an experiment mechanistically where we
01:08:42 took cells that were very sensitive to metformin, and we put it in a mouse. The tumor grew. We gave
01:08:49 the mouse metformin, the tumor shrank. And that tumor, we put that yeast NDI1 back in,
01:08:55 so it would be refractory. And guess what? The tumors came back. So again, mitochondrial complex
01:09:01 one inhibition by metformin explains the anti-cancer effects. I think that part is more
01:09:07 widely accepted. What was the cell of origin of that cancer?
01:09:11 That was, we did it in two. We did it in a lung cancer and we did a colon cancer.
01:09:15 And the metformin was delivered orally in both cases?
01:09:18 Orally, both cases in the drinking water.
01:09:19 So how do you think it made its way into the lung cancer?
01:09:22 Yeah, I'm going to tell you in a second.
01:09:24 So what we had noticed was not only we, many people had noticed that if I took 60 cell
01:09:30 lines, 10 cell lines, one or two would respond.
01:09:34 In culture, the other 10 wouldn't care.
01:09:37 I could go to 100 millimolar, they wouldn't care, barely.
01:09:40 A student in the lab, Karthik Vassan, he did a simple screen.
01:09:43 He took a very sensitive cell line to metformin in culture, the same one in vivo that in a mouse
01:09:50 reduced, and he added metformin to it. And it killed that cell. He added it at a dose,
01:09:56 it killed it. He basically using CRISPR, the CRISPR technology to knock out every metabolic
01:10:02 gene. So he's got 3,000 different clones now with all the metabolic genes knocked out.
01:10:08 2,000 of them, like 1,000 of them are so fundamental for life.
01:10:12 Incompatible.
01:10:13 Incompatible.
01:10:14 The other, I don't know.
01:10:14 I don't remember what the numbers were.
01:10:16 Let's say there was 1,000 that lived.
01:10:17 And then he asked, if I give those metformin, who lives?
01:10:21 One guy lived.
01:10:23 One clone lived.
01:10:24 One guy could live.
01:10:25 It lost the organic cation transporter.
01:10:28 So it couldn't bring metformin into-
01:10:30 The plasma membrane transporter.
01:10:32 If you lose it, it laughs at metformin.
01:10:36 It doesn't care.
01:10:37 Okay, why is that important?
01:10:39 Wouldn't it be nice to do a clinical trial based on
01:10:41 whether you're positive for that transporter or not?
01:10:45 Do we know that when we screen human cells, can't we screen for that cation, at least in the,
01:10:51 I mean, that should be knowable. There's three of these transporters, aren't there? 1.00
01:10:54 Three transporters, yeah, yeah, yeah.
01:10:55 Do all three of them transport metformin equally?
01:10:57 Seems like, at least in the cancer one, is organic cation transporter three.
01:11:01 But your point is, can you not come up with a diagnostic test?
01:11:05 So I'll play it one step forward. It's very important to know how frequently that's mutated,
01:11:09 because if that's mutated a lot, it could explain why you have failures in clinical trials. If it's
01:11:16 mutated very little, that would suggest that that's not the reason. In other words, it's not
01:11:20 the failure to deliver metformin sufficiently to the tumor that causes the failure.
01:11:24 Right. But what I'm going to argue is tumor cells may not even have it to begin with.
01:11:28 You're saying they lose them?
01:11:30 No, no, no. So the experiment that we did, we made genetic knockouts in an unbiased way. And we said,
01:11:37 let's lose in each cell individually. But the cells were what to start?
01:11:41 They were positive. They were positive, but lots of them are not positive to begin with.
01:11:46 Let me back up for a second. Are you telling me right now, you know, my liver has these cells?
01:11:51 Let's just assume I don't have any mutations. You know, my gut has them.
01:11:55 Kidney has them.
01:11:56 My kidney has them. You don't know if my pancreas has them?
01:11:58 Most of the cells don't have high robust organic cation transporters or else they wouldn't
01:12:03 and high levels of it. And what I'm saying is, when you look at the cancer profile...
01:12:07 Yeah, but you said it only gets in the blood at 10 micromolar.
01:12:11 Right. So you have this huge drop-off when you go from gut to liver to blood. So if the blood
01:12:18 only has 10...
01:12:19 10 to 20 micromolar.
01:12:20 Sure. If the gut only has 10...
01:12:21 Maybe at peak, it goes a little higher.
01:12:22 Okay. But still, is that even enough to get it into cells should they have the transporters?
01:12:28 Yeah. So when we've measured it in the tumors, you can find it. And more importantly,
01:12:33 The best experiment we can do is when we give NDI1 and we abrogate the effect.
01:12:38 So there was sufficient amount of metformin.
01:12:40 So you see a big enough delta with the two different complex ones, even at that lower
01:12:45 delivery?
01:12:46 Well, 10 micromolar gets enriched 100x in the mitochondria.
01:12:50 If it gets delivered because of the potential, so it's cationic, metformin is positive,
01:12:56 and you're pumping a negative.
01:12:58 Electron transport's working, it's pumping negative, and you bring it in.
01:13:02 So people have estimated anywhere from 100 to 500X, X-metformin accumulation in the matrix
01:13:07 where it binds to complex one.
01:13:09 But again, we can argue about, did it work?
01:13:12 You're saying we don't even know if a breast cell has this transporter on it? 0.96
01:13:16 No, what I'm saying is we didn't go back and try to figure out where the breast cancers
01:13:22 that were given, we didn't stratify them by organic cation transporters.
01:13:25 No, no, no, totally get it.
01:13:26 But I'm saying in the wild type, for a woman who's listening to this podcast right now,
01:13:30 It's likely that her actual mammary tissue does not contain the transporter.
01:13:36 Probably doesn't.
01:13:36 So then it seems very unlikely that when she develops cancer,
01:13:40 that it's somehow going to randomly mutate in developing the transporter.
01:13:43 Not mutated, but maybe the oncogenes.
01:13:46 Because remember, these transporters are not designed to bring in edformin.
01:13:50 They do have other functions to bring in other organic cations, potentially.
01:13:55 I don't know which...
01:13:56 It's active?
01:13:56 It's ATP exchange?
01:13:58 I don't actually know that.
01:13:59 Okay.
01:13:59 I actually don't know that.
01:14:01 How positive is metformin?
01:14:02 I think serotonin, and I don't remember this, Peter.
01:14:06 I want to say there's something important that it transports.
01:14:09 Okay.
01:14:09 I heard it's at a low level.
01:14:11 Forgive me.
01:14:12 But the simple point being is that we didn't go back and stratify based on the transporter.
01:14:18 EGFR inhibitors are given to someone has a mutation in EGFR.
01:14:23 Herceptin is given, going back to the mammary, breast cancer, to HR2 positive.
01:14:29 so we didn't do that. Another way you could do it is, let's take a tumor that is not FDG-positive
01:14:35 for glucose. It doesn't take up a lot of glucose. There's many tumors that don't, as you know.
01:14:40 Now we give the patient metformin. If the tumor starts to light up with glucose, you bet metformin
01:14:45 got in and inhibit mitochondrial complex one. You could stratify it based on that, right? Is your
01:14:51 tumor, metformin responsive by FDG PET, low versus high. Is it your hypothesis that if metformin is
01:15:00 going to have efficacy in an oncologic setting, it's going to do so through mechanism number two,
01:15:06 going back to the original four things we talked about, where mechanism number two is by inhibiting
01:15:11 complex one, it's not so much that it's inhibiting the ability of the tumor to generate ATP, but more
01:15:16 importantly, it's the ability of the tumor to generate building blocks for cellular growth.
01:15:21 It's the anabolic targeting. Absolutely. Absolutely. Because that electron transport
01:15:26 makes the TCA cycle go, oh, and you inhibit electron transport, TCA cycle, which makes
01:15:32 the metabolites for growth are lowered, and now you can grow as well. But all of this depends
01:15:38 on metformin being efficiently coming in through the transporters, probably through the mitochondria.
01:15:43 We've been trying to find how it gets into the mitochondria.
01:15:45 We haven't figured that out.
01:15:47 Yeah, we haven't figured it out.
01:15:49 We don't know how mitochondria gets from the cytoplasm into the actual inner matrix.
01:15:56 I don't know how metformin gets into the mitochondria.
01:15:59 I know how it gets from the cell membrane.
01:16:02 It needs those organic cation transporters, one, two, or three.
01:16:05 Yeah.
01:16:05 Actually, the screen was designed to try to figure that out.
01:16:08 We didn't, but we stumbled upon something simpler.
01:16:11 And this is just a very super naive question.
01:16:13 but are we at the point technologically where we can do time-lapse electron microscopy and
01:16:19 actually watch something like metformin travel throughout the site? I don't think so. But
01:16:24 someone did this fancy cryo-EM technology, which I'm not familiar with, to the best of the structural,
01:16:30 and now they can see where metformin binds to complex one. That's assuming it's already inside.
01:16:34 It's already inside. Yeah, yeah. This is different, but it's pretty cool. They figured
01:16:38 out in this boot 45 subunit, exactly the binding sites of metformin. Very cool. And they also made
01:16:45 a point that it didn't inhibit any of the other complexes because some people argue complex 4
01:16:50 might be a site. I don't buy any of that and nobody does in the field other than a few people,
01:16:55 but I'm open to it. Complex 1 clearly is inhibited by mitochondria. This NDI1 is a good way to test
01:17:02 to test the necessity of complex one inhibition. So going back to, should you and I take metformin?
01:17:08 Okay, I can lower my glucose. That's not a bad thing. The cancer effects, well, you could argue
01:17:13 that for us, prostate cancer, that if our prostate cancers, for whatever reason, God forbid,
01:17:20 are lesions, if we were to get them as we age, they happen to be organic cation transporter
01:17:25 positive. Big if. Then maybe there's some efficacy there. But is that reason enough?
01:17:30 And even if you deliver it intravenously to put a higher concentration in circulation,
01:17:36 it's either binary. Either you have the cation transporter or you don't.
01:17:39 Even if you drove the blood concentration up to a log, you wouldn't.
01:17:43 No, no. Exactly. Because we gave quite a high metformin to kill in that screen.
01:17:49 When that cancer cell lost the organic cation transporter, it became totally refractory to
01:17:54 metformin.
01:17:54 So then is it your suspicion that if you took a woman with breast cancer or a man with lung
01:18:00 cancer, and you could screen their tumor, and indeed, by some good fortune, they had
01:18:06 the OCT on it, that metformin would be a potentially potent anti-tumor drug?
01:18:13 Potent is a famous last word.
01:18:15 Yeah, exactly.
01:18:15 How much will it prevent proliferation?
01:18:17 It will not decrease proliferation, but the best thing it'll do is they'll stop consuming
01:18:21 oxygen, and the local oxygen concentrations will start to increase in a tumor, which would
01:18:26 make it better for radiotherapy and immunotherapy.
01:18:29 one of the challenges in immunotherapy, there's many, but one of the key ones is the hypoxic
01:18:33 tumor microenvironment is very immunosuppressive. So anytime you can increase oxygen levels,
01:18:40 that could be helpful for radiation, as well as that, along with not making the building blocks.
01:18:46 But we don't screen for any of this stuff. And because metformin is so cheap, who's going to go
01:18:50 and do these studies, go back and do all of this? But I guess from a geoprotective, maybe you take
01:18:56 it just in case. So this is more bullish than where you were eight years ago. Or seven years
01:19:01 ago, I said, are you going to take metformin? And you said, no, I need to see more data.
01:19:06 Yeah, yeah. So at least I know now why it wouldn't work in cancer and why it may work in cancer. I
01:19:11 have a good explanation for it. I got a good explanation for the glucose lowering. So I'm
01:19:15 going to give you the third one. This is the one every day I wrestle with, Peter. Should I do it?
01:19:20 Should I do it? Inflammation. I take a statin now, even though I don't need to. I take a very low
01:19:24 dose statin. At 50, I decided to go to my doctor, who's a great doctor, you know, also with Indian
01:19:29 genetics. I had pretty good numbers, listening to you, of course. So I have something for that.
01:19:34 I exercise, I have something for my muscle, be social, etc., all the sleep, etc. But for
01:19:40 inflammation, and I've been thinking a lot more about inflammation, so the city of Chicago,
01:19:44 which had terrible pollution for a long time, really cleaned up its act the last 20 years.
01:19:49 except this past summer, thanks to the Canadian wildfires, it's raging. But at one day, I think
01:19:55 we were the worst in the world. Trust me, the last 20 years, you can look at the data. We're
01:20:00 not a terribly polluted city, at least where I live. We've done trees on top of trees on
01:20:04 homes, et cetera. We've done a lot to make ourselves not. And now we have this. What are
01:20:09 you going to fight against pollution? Pollution-induced inflammation. So my friend Scott
01:20:13 Budinger and Gokhan Mutlu at Northwestern. Years ago, they were giving Beijing-level pollution
01:20:19 to mice. And one cytokine goes up robustly in humans and in mice, IL-6. And IL-6 makes you
01:20:26 prothrombotic. Therefore, you're susceptible to cardiovascular injuries, an MI, for example.
01:20:32 Okay. They started taking alveolar macrophages and giving it low-dose pollution in vitro. And
01:20:39 they noticed that the pollutants, this particulate matter, these small particles were going in the
01:20:44 mitochondria and increasing that H2O2 signal. And they could show that H2O2 signal was responsible
01:20:50 for the IL-6 production. So it's pollution, particulate matter pollution, mitochondria,
01:20:57 increasing H2O2 not to kill as a signal for inflammation.
01:21:02 And by the way, does the pollution have to be PM2.5?
01:21:06 I think so. It was that one. That's what they did. Yeah. The crazy thing is, I was like,
01:21:10 oh, Scott, you got to put metformin. And he goes, what do you mean? Metformin inhibits complex one
01:21:16 and it'll prevent the H2O2 from being released. He's like, okay. So they did it in vitro and
01:21:21 in vivo. It's a paper in cell metabolism. And beautifully, they could show in vivo,
01:21:26 giving it in the drinking water, that it lowered the IL-6.
01:21:30 And is that because the liver is making...
01:21:33 The alveolar macrophages.
01:21:34 It's the alveolar macrophages?
01:21:35 It got to the alveolar macrophages.
01:21:37 They took it up because we could see in the alveolar macrophages.
01:21:41 How are they getting the metformin?
01:21:43 They're taking it up.
01:21:44 Out of the blood?
01:21:44 Out of the blood.
01:21:45 So they have...
01:21:46 They had the transporters, but they're good at, I think, at also taking up stuff.
01:21:51 What we want to do is put NDI1 back in those macrophages to definitively show it did take
01:21:57 it up and inhibit complex one because it could have been an effect from somewhere else.
01:22:01 Maybe the gut, everything.
01:22:03 But the key point is we're still working on the mechanism, Peter.
01:22:07 And we've done, by the way, we've given flu with metformin.
01:22:11 There was always a COVID signal with metformin decreasing the inflammation.
01:22:16 So in mouse models of SARS-CoV-2 or influenza, when people give drinking water metformin,
01:22:21 it lowers the pathology.
01:22:23 But my simple point was I'm going to be exposed to pollution.
01:22:26 Again, there's no human data with metformin and pollution.
01:22:29 measuring CRP or something like that for a couple of months and seeing if it was lower
01:22:34 at a population level. Do you think IL-6 would be more sensitive than CRP?
01:22:40 I think CRPs would be equally sensitive, I think. But again, people just haven't designed the trials
01:22:45 correctly to think about this. So here's the last one about inflammation. Do you know what
01:22:50 clonal hematopoiesis is? Yes. So this is as we age... But tell people because it's an important
01:22:54 part of heart disease. We probably don't spend enough time talking about it. Yeah. So as we age,
01:22:58 are hematopoietic stem cells, which make all our blood cells, including our T cells and our B cells
01:23:04 and our red blood cells and our platelets. As we age, those can pick up a particular mutation,
01:23:10 and actually mutation in the enzymes that run epigenetics largely, and they become rogue clones
01:23:15 and they overtake. And they somehow contribute to cardiovascular disease, definitely inflammation,
01:23:22 and the level of clonal hematopoiesis can range from 3% to 20% and of these rogue clones taking
01:23:27 over as we age. So UK Biobank did this study. They looked at clonal hematopoiesis, and they
01:23:34 somehow, and I'm not an epidemiologist, controlled for diabetes and everything. People on metformin
01:23:39 had lower incidence of clonal hematopoiesis, 450,000 UK Biobank. The same people made a mouse
01:23:47 model of clonal hematopoiesis, and they gave metformin a decreased clonal hematopoiesis.
01:23:53 How much?
01:23:54 Very significantly. It was quite remarkable. Here's the best part.
01:23:57 some smart reviewer said, you should put NDI-1 and show me his complex one. And it was. So in
01:24:03 other words, metformin binding to complex one prevented those clones from outgrowing from the
01:24:09 mechanism you pointed out because the building blocks weren't there. But again, how are we
01:24:13 getting so lucky that these cells have OCTs? To be honest with you, the dosing they did
01:24:20 was 50 micromolar in vitro to have some of these effects. I was shocked.
01:24:24 And they were doing this in human cells?
01:24:27 They did it in mouse cells.
01:24:29 Three papers came out at the same time to the same conclusion.
01:24:32 So speaking of reproducibility, three different ways.
01:24:35 Two of them were in Nature, the other one was in Nature Communications.
01:24:38 All three of them said if you inhibit electron transport chain,
01:24:41 you can prevent clonal metapoesis, and the best drug that is safe is metformin.
01:24:46 So Peter, let's just wrap up the metformin.
01:24:48 There's a couple of lessons in the metformin.
01:24:51 On the mechanism side, and we're going to get into some of your other favorite supplements,
01:24:56 perhaps, we should first think about when you take an oral supplement or an oral drug,
01:25:02 where does it go?
01:25:03 Does it accumulate everywhere or does it only go certain places?
01:25:06 The second thing we have to know is what is its target?
01:25:09 I've argued it's complex one because I've made a complex one that is refractory to metformin
01:25:15 binding but works like complex one.
01:25:17 So someone should always show me the target and make that target work perfectly fine,
01:25:22 but not bind to metformin or whatever other drug or supplement.
01:25:27 And the third one is maybe you don't even care about where it goes and what it binds
01:25:32 to.
01:25:32 Does it work in humans, not in mice only?
01:25:36 And so the data suggests you tell me if you agree with this.
01:25:40 In a normal person, it'll keep your glucose levels down.
01:25:43 If you take it before a meal, not a bad thing.
01:25:46 If you get lucky, if it has that transporter, then it will perhaps lower the cancer clones
01:25:53 from arising, and if you're lucky to have that.
01:25:56 The third one is clonal hematopoiesis that happens with agent lowers, according to these
01:26:01 studies, and in our study with pollution, and in some studies that people have done
01:26:06 with T cells, it seems to be a low anti-inflammatory agent.
01:26:11 So is that enough for people to take it?
01:26:13 So what are the risks?
01:26:14 The risk is B12 deficiency, but you can fix that.
01:26:17 The other one is citrulline.
01:26:18 You can easily take supplement for that.
01:26:20 People get nausea, so people sometimes people don't take it, but many people don't.
01:26:24 So that's where we're at.
01:26:25 Do you think it cross-reacts or interferes with other glycemic agents such as GLP-1 agonists?
01:26:33 What do you think?
01:26:34 I've asked people that.
01:26:35 They say no.
01:26:35 I don't think I have an informed enough opinion.
01:26:37 I just don't.
01:26:38 Yeah, I don't either.
01:26:39 There are people who do both, as you know.
01:26:41 I just don't.
01:26:42 So it's the inflammation part.
01:26:44 because I'm not going to take an NSAID. I'm not going to take a leave every day.
01:26:48 I take it sometimes. It's pretty potent. But then the question becomes like,
01:26:52 why did aspirin fail in the ITP? Why would COX inhibition, which should be reducing inflammation,
01:26:59 had no impact on... Well, it reduces different kinds of inflammation, perhaps.
01:27:03 We can show metformin inhibits IL-1 beta, IL-6. So what would we need to do in humans?
01:27:09 I've lost track. Is TAME happening? What's going on? I don't know. I don't know. But again,
01:27:13 And the cancer trials, the TAME trials, every trial in metformin, because it's cheap, it's
01:27:20 been guided smartly by whatever data is in humans, could we redo these trials based on
01:27:26 mechanism?
01:27:27 Mechanism being the insights we have now.
01:27:29 But glucose monitors is to see over a year how well did the metformin that people took
01:27:35 just to know whether it did anything.
01:27:38 Maybe it doesn't.
01:27:38 Maybe some people, for whatever reason, it doesn't get absorbed.
01:27:41 Maybe their transporters are low.
01:27:42 So have some indication and maybe measure CRP or some other, measure clonal hematopoiesis.
01:27:49 There's ways to do that.
01:27:51 There is all of this sort of stuff.
01:27:52 As far as the cancer, that's almost impossible.
01:27:54 You're just taking it, something that may help protect against, or if you get an early
01:27:59 lesion, it might slow it down.
01:28:01 But I like the inflammation and the lowering glucose as the two actionable ones.
01:28:06 And is there anything else that really can do that?
01:28:08 Well, I think if you're lowering CHIP, that's pretty interesting.
01:28:11 Yeah, yeah. We'll have to see how well that manages.
01:28:15 And that hasn't been demonstrated in human cells yet?
01:28:18 Well, it has. It has been also demonstrated in the UK Biobank as just a correlation.
01:28:23 But it hasn't been proactively tested in humans?
01:28:25 No, no, no. You mean as a clinical trial? No. Someone used to do that, but it'll take five years.
01:28:31 But that would be a very interesting trial in a high-risk population.
01:28:34 You take a high-risk cardiovascular disease population that is otherwise well-managed.
01:28:38 Because one of the questions I find interesting in ASCVD is, I'm interested in the topic of
01:28:42 residual risk. So why is it that some people can have significant risk, then you manage them well
01:28:51 with blood pressure and lipid control, but then they still progress, disease progression occurs
01:28:56 at different rates. There's some residual risk beyond the ApoB and beyond the hypertension,
01:29:02 and let's assume they're not smoking. And how much of that is chip related?
01:29:05 And if you can find that population and you do an RCT there with and without metformin and you track the hematopoiesis, the clonal hematopoiesis question, I think that could be very interesting.
01:29:18 Yeah. By the way, speaking of heart disease or heart failure, speaking of metabolism, one of the best new drugs are these SGL2 inhibitors. The SGL2 is basically in the kidney. So you pee out, they call it sweet pee.
01:29:31 The urine, you just pee out the glucose into the urine and that somehow is communicating to the
01:29:37 heart and telling it, a failed heart, that you're good to go now. The idea that heart failure is
01:29:43 due to mitochondrial dysfunction is the one I really have my doubts side in humans. I just
01:29:47 don't think the evidence really points to that. You can make a mouse model where the heart fails
01:29:52 because the mitochondria are failing. Right, but that doesn't mean that's...
01:29:55 That's what's happening. And the results are mixed in humans. But the best evidence to me is that
01:30:00 you put somebody on an SGL2 inhibitor, it somehow globally reprograms their metabolism. And that's
01:30:06 a very loosey-goosey, non-mechanistic term. Maybe increases a little ketones or fatty acids,
01:30:12 but their heart works fine now, which means there could not have been intrinsic mitochondrial
01:30:16 defects. Because if there were, SGL2 inhibitors wouldn't work so well.
01:30:20 Now, I want to talk about a whole bunch of supplements that get talked about a lot.
01:30:24 Before I do, though, I just want to go back to something you said at the outset. I asked you,
01:30:27 how would you measure mitochondrial function? And you said, I'd put a needle in somebody and
01:30:32 pull out tissue. But that's important because there are lots of people out there that are
01:30:37 hawking tests that are claiming they have tests. They have blood tests. They have breath tests.
01:30:42 They have all sorts of tests to measure mitochondrial function. As one of the world's
01:30:46 experts on this topic, are you aware of any blood test, breath test, any sort of test that a person
01:30:54 can do to measure their mitochondrial function? If they see this, what should they be thinking?
01:30:58 I have not looked at all these tests. I don't follow these tests. I don't care to. Simply
01:31:03 because in a perfect world, I can't think of how I would design it for all the reasons we just
01:31:09 talked about. That's the real problem. I mean, look, if I had one, then maybe this struggling
01:31:13 scientist professionally and personally would come up with one, Peter. But I got nothing other
01:31:18 than a cheap drug called metformin and a glucose monitor. It's difficult for me to imagine how that
01:31:23 test looks like and whether it reproducibly measures something that has value? I'm assuming
01:31:29 what these tests are trying to measure are... This content? Well, yeah, I assume, I'm also not an
01:31:35 expert in this whatsoever. I assume they're measuring metabolic intermediates and they're
01:31:40 somehow trying to impute based on your orginine, arnithine, citrulline levels, alpha-ketoglutarate
01:31:47 levels. Oh, based on that, based on the ratios and levels of all these things, we can tell you
01:31:51 how your mitochondrial function. Or acylcarnitine. Yeah. Why is that bogus in your mind? Well,
01:31:57 because A is in steady state. It doesn't really tell you flux, which is how fast the system is
01:32:02 running or not running. You could see an increase in something. Is that because you're running so
01:32:06 fast and you still have a lot or is it something backed up? That's problem one. Yep. That's the
01:32:11 whole CTAP inhibitor problem back when we were dealing with that drug. Yeah. So it's just when
01:32:16 And I myself haven't done a deep dive on something.
01:32:19 I generally try not to be overly critical, but I'm just making a conceptual point that
01:32:25 if you and I sat together for an afternoon and said, here now, tell me all the things
01:32:29 I could measure and how would I measure it?
01:32:31 Could I come up with a test?
01:32:32 No.
01:32:33 All right.
01:32:33 Let's talk about some of the most popular supplements that people promote.
01:32:38 Can I just finish just with cancer real quick?
01:32:40 Yeah.
01:32:40 We didn't touch cancer because this is another misnomer.
01:32:42 So the original hypothesis of cancer, the number one hypothesis of cancer, not number one, but the oldest from the 1920s was by a gentleman in the Warburg, a fact that many people have heard.
01:32:54 So Otto Warburg got a Nobel Prize for the discovery of cytochrome C oxidase, which is the main oxygen-consuming enzyme of the electron transport chain.
01:33:03 He truly did his PhD on cytochrome oxidase kinetics.
01:33:06 So for me, Otto Warburg has a place for the discovery of that enzyme electron transport chain.
01:33:12 So Otto Warburg, in the 1920s, noticed that cancer tissues, those make a lot of lactate
01:33:18 on a tabletop compared to normal tissues.
01:33:20 There's plenty of oxygen.
01:33:21 And so if you have oxygen, you shouldn't be making lactate.
01:33:24 So he actually made an intelligent guess, which is that mitochondria of those tissues
01:33:28 of the cancer is dysfunctional.
01:33:31 Their electron transport, he called it injury to respiration, his famous line, is a prerequisite
01:33:36 for developing cancer.
01:33:38 Today, we know that many cancers that make a lot of lactate don't do it because electron transport or injury to respiration.
01:33:46 In fact, 95-98% of cancers have a very intact electron transport chain, TCA cycle.
01:33:54 And the reason is because they use it to make ATP, but also to make those anabolic precursor, the metabolites for growth.
01:34:01 There are a few outliers that have a TCA cycle mutation or an electron transport chain mutation.
01:34:07 Those tumors that arise, they basically take the macromolecules for growth, the metabolites
01:34:13 from growth, from the blood.
01:34:15 They're good scavengers.
01:34:16 Yeah, this is an important point to tease out.
01:34:17 So the Warburg effect is an effect.
01:34:20 Most cancers adhere to it.
01:34:22 It's the causality that's incorrect.
01:34:24 It's not that the Warburg effect is the result of deficient electron transport.
01:34:30 It's that the Warburg effect is there as a result of a cell that needs to reproduce
01:34:35 and grow and grow and grow and create building blocks. The first time I read this was in that
01:34:40 very famous 2009 science paper with Matthew and Lou and Craig. So very important distinction.
01:34:47 But unfortunately, this is sort of where the internet and people who maybe don't fully
01:34:52 understand this will turn it into cancer is a mitochondrial disease, and it's all about your
01:34:57 mitochondria. And if you just take mitochondrial supplements, you'll never get cancer. Or if you
01:35:00 have cancer, just take mitochondrial supplements, you're going to be fine. This is complete and
01:35:04 utter nonsense. Yes. Okay. So let's turn to some famous mitochondrial supplements. Urolithin. 0.78
01:35:12 What can you tell us about urolithin? We're going to use the metformin principles all over again.
01:35:17 Oral, first pass, gut. The gut cells do take it up. The second pass very quickly, liver.
01:35:23 I actually didn't know this until recently because I went back and read a very nice paper. I think
01:35:29 one of your guests previously might've been on, I think it was on the paper on inflammation and
01:35:33 urolithin. If you look at the supplementary data, how much is in the plasma of urolithin of those
01:35:38 people who took it? Picograms. Undetectable. Because the liver puts glucuronic acid on it.
01:35:46 So it's urolithin and conjugated, which then is in the plasma. So you can barely detect urolithin
01:35:55 in the plasma. It's conjugate, urolithin plus this sugar moiety, is higher, like 5 to 10 micromolar.
01:36:03 That moiety cannot get into a cell.
01:36:05 Your litten can.
01:36:06 So what breaks the conjugate?
01:36:08 So there are enzymes that can break that conjugate.
01:36:12 They're usually found around immune cells, sometimes in muscle repair tumors.
01:36:16 But this is a bit of a conundrum I don't quite understand.
01:36:20 And I'm sure you appreciate where I'm going with this.
01:36:22 It's like, well, hang on, how does this work?
01:36:24 This thing rapidly becomes...
01:36:26 So either it's having effects on the gut directly, which it might,
01:36:29 and we know how important the gut is.
01:36:31 The other thing is that when it's made a conjugate, it has to be deconjugated.
01:36:36 And that's happening in my reading of the enzymes that do this tend to be more related
01:36:42 to immune cells, okay?
01:36:44 So that's part one.
01:36:45 The second thing is like with metformin, what's its target?
01:36:49 So with metformin, people debated, is it complex one?
01:36:52 Is it not complex one?
01:36:53 Is it complex four?
01:36:55 Is it something else?
01:36:56 The way we went about showing it's complex one is we found a refractory version of
01:37:01 metformin that wouldn't bind and to show it was complex one. So with urolithin, they say it's
01:37:06 mitophagy, that it promotes bad mitochondria, it gets rid of them. I've missed three steps.
01:37:12 How is it even getting into a cell? Well, I don't know that. So the only way it could get into a
01:37:18 cell is that locally, immune cells, for example, again, I don't know the literature that well on
01:37:24 it. Do we know if there's a urolithin transporter that can get unbound or unconjugated urolithin?
01:37:30 I don't think the conjugated one can get in. I think the unconjugated for sure gets in.
01:37:34 Clearly, somebody could label urolithin and give it to somebody and then look at where it's taken
01:37:39 up. Has that experiment been done? I've never seen it. So that's what the metformin experiment
01:37:43 was. Someone took a C11. They said, oh my God, it's in the gut. Someone did an FDG pad. Oh my
01:37:48 God, it's in the gut. People like me say, okay, let's focus on the gut. Again, I'm just using
01:37:54 the principles of metformin, which can be used the principles of urolithin. Where does it go?
01:37:58 what I do know is that they measured it in the plasma. It seems like a lot of it
01:38:03 is converted in the liver to this urolithin plus this sugar moid. That was my simple point.
01:38:09 If that's the case, then it has to get deconjugated somewhere in the body,
01:38:14 maybe in immune cells, because immune cells can supposedly release the enzyme that deconjugates
01:38:19 it. And then the urolithin gets into that localized population.
01:38:23 So if you could assume it gets into a cell, how likely is it that it can induce mitophagy?
01:38:30 Or what's the evidence that it is doing that?
01:38:32 People have seen it induce mitophagy or mitochondrial biogenesis, but where is the target?
01:38:38 It's been 10 years.
01:38:39 Where is the target?
01:38:41 I don't think anybody's ever told me a target or published a target.
01:38:44 And it's interesting because metformin is free.
01:38:47 There's no money to be made in it, but yet the research has been done.
01:38:52 why is it not the case in urolithin that that's being done? In other words,
01:38:56 is the argument that urolithin is a supplement and that it's over-the-counter and therefore
01:39:00 it's not worth studying, whereas metformin is a regulated drug and that's why it's worth studying?
01:39:06 I mean, I'm trying to understand why there is such a glaring gap in knowledge for over-the-counter
01:39:13 supplements. I would argue there isn't. It's just how efficacious they are. Peter, forgive me. I
01:39:20 have to go back to a supplement that's widely used, berberine. Oh, yes. Oh, you're going to
01:39:26 like this. So berberine people take. Newsflash, berberine doesn't look like metformin. In our 0.64
01:39:32 studies, when we give mice berberine, it lowers the glucose levels, okay? If we have NDI1, that
01:39:40 yeast refractory, in the gut, glucose levels go up. So berberine, as far as I can tell, works
01:39:48 exactly like metformin. And gee whiz, metformin is probably cheaper than berberine and is
01:39:53 regulated. Use metformin if you're going to use berberine. Sorry.
01:39:57 Same concentrations you're seeing in berberine as metformin?
01:40:00 We are using the concentrations of berberine that were effective in lowering in mice.
01:40:05 We just have to. So we use a concentration of metformin that's widely used to lower
01:40:09 glucose levels. We use berberine to lower glucose levels, the lowest dose.
01:40:14 It is always interesting that people do prefer a supplement over a drug.
01:40:19 It's like, I'd rather have something that's unregulated and I cannot verify the quality
01:40:23 versus a drug.
01:40:24 Right.
01:40:24 But my point is, as far as we can tell, and it's in our preprint paper, people can see
01:40:28 it, it acts like metformin, even though structurally it's different.
01:40:32 My point is, it's probably like metformin.
01:40:34 But you don't have the granular detail for berberine in terms of, you don't actually
01:40:38 know where it's binding complex one.
01:40:40 You just know it is working on complex one based on the experiment.
01:40:43 Right.
01:40:43 Right. So let's go back to urolithin. You could ask, now, why don't you work on urolithin?
01:40:48 You're a mitochondria guy. Here's another new fascinating drug. Well, okay. So we could start
01:40:53 to figure out, there's ways that you can figure out how a drug or a metabolite binds to a protein.
01:40:59 There are new techniques. They're called like proteome thermal shift assays. So there's ways
01:41:04 to do this. I'm waiting for the aha data in humans or even in mice and the data. So the human trial
01:41:11 and muscle. I mean, again, the trials are small. They're not gee whiz. The one that I have liked
01:41:18 recently, there was a mouse trial with anti-tumor immunity that was pretty good. They gave it to see
01:41:24 if your leptin would make T cells more effective against a tumor. What did that experiment show?
01:41:30 It helped. Why do you think it did? They argued through mitophagy and they did a nice experiment.
01:41:35 They knocked out the thing that controls mitophagy and then it didn't work as well. So it's as good
01:41:41 of a biological study. So that got me thinking a little bit about urolithin. But the other one is
01:41:45 they gave it to people, and they looked at CD8 T cell, whether they were exhausted, and I think
01:41:51 it was in the elderly. And you have some amount of exhaustion, and you had a little bit less with
01:41:55 urolithin. And again, this is a paper where they show that the plasma is mainly UDP. Sorry, it's
01:42:01 urolithin bound to sugar moiety. But again, there's an effect there, a decreased inflammation.
01:42:08 If we're going to use metformin as our baseline, it's the one we know the most about,
01:42:12 where do you put the promise of urolithin relative to metformin?
01:42:15 I don't see it lowering glucose levels. I don't see any data. Well, I guess the
01:42:18 anti-tumor data was good. I think with a lot of these supplements, there may be a window.
01:42:23 For example, maybe urolithin could improve anti-tumor immunity and you should use it
01:42:28 with CAR T cells. People get CAR T cells for a couple of months. Maybe you could do a urolithin
01:42:32 trial in that. Why not? Based on that one study. But compared to metformin, I don't see how
01:42:38 it's not remarkably lowering glucose effects or having other effects that we just discussed with
01:42:43 metformin. Not enough to make me say, let's use that. Okay. What about alpha-ketoglutarate?
01:42:48 I like that one a lot, and I study it myself. Actually, I study a different version. Something
01:42:54 in the family of alpha-ketoglutarate. The reason I like it is because alpha-ketoglutarate, we do
01:42:58 have targets, probably too many, 75. If alpha-ketoglutarate is there, it's going to run
01:43:03 your demethylase enzymes working well. It'll potentially keep DNA methylation levels down,
01:43:10 your so-called voodoo epigenetic clocks. Is it keeping methylation down or is it
01:43:15 reducing methyl groups? No, no, no. So the methyl groups put it on, the DNA. The enzymes that get
01:43:21 rid of it, it keeps those enzymes from working well. Here's the only issue. How much do you need
01:43:27 for alpha-ketoglutarate in a cell to run those enzymes maximally, 100 micromolar. You have a lot
01:43:34 of alpha-ketoglutarate. Is it ever rate-limited? Is it ever rate-limiting? I don't know that.
01:43:39 As we age, it does go down, but does it go down enough? So what's the experiment? What's been
01:43:44 done? Well, people are now giving alpha-ketoglutarate. There's a famous study. I think
01:43:48 Brian Kennedy's group did that with the females had a better outcome than males did. The mice did,
01:43:54 and they're doing human trials, and hopefully they'll do them enough that we'll get parameters.
01:43:59 But I could imagine like alpha-ketoglutarate, again, working for inflammation under certain
01:44:04 conditions. One of my favorite studies, and I wrote a perspective on it, it's not my study,
01:44:09 came out of other groups, where they gave alpha-ketoglutarate genetically, they manipulated
01:44:14 or a supplement, and it helped against colitis. It happened against 5-FU, the chemotherapeutic
01:44:20 drug. So in other words, it maintained gut health. It promoted stem cells to become more secretory
01:44:26 compared to absorptive, which helped maintain gut health. Could you imagine giving alpha-ketoglutarate
01:44:33 in those settings? So instead of thinking of a geroprotective, to me, they're going to be niche.
01:44:39 And I think people who are doing them maybe should think about them. You love this study. I know I do.
01:44:44 The rapamycin vaccination one. Yeah, exactly. I love that study.
01:44:47 But to do this, you really need to go down an IND pathway as opposed to a supplement pathway.
01:44:53 You have to turn this into a drug. You have to have an indication. You have to be able to make
01:44:59 a claim. You have to be able to test a meaningful and serious hypothesis. Okay, citrulline.
01:45:05 Well, we just said that it can... Potentially with metformin.
01:45:07 Potentially with metformin.
01:45:09 Okay. Carnitine.
01:45:11 Well, carnitine helps get fatty acids into the mitochondria. That's what carnitine does. The
01:45:16 question is... Is it meaningful? Is it rate limiting? Is it rate limiting? I go back to the
01:45:21 rate limiting. Do you, you and I, I assume you're still a meat eater. I am. And even people who
01:45:27 don't eat meat, they probably get sufficient amount of carnitine to have your fatty acids
01:45:32 working. All right. The big one, CoQ10. I think statins, it makes sense sometimes because it can
01:45:41 hit the CoQ pathway upstream? So you can imagine certain statins maybe that get in the muscle
01:45:46 high enough are lowering CoQ levels. Does it get to the point where CoQ again becomes rate limiting?
01:45:53 Anecdotally, I mean, you know this better than I do, Peter. People say that the CoQ helps them.
01:45:57 I feel like the trials have not been successful.
01:45:59 Not shown that, yeah. Again, there's a bioavailability problem, but for what else
01:46:05 would you use it for? For normal health? No, you have enough CoQ.
01:46:08 Okay. Now we've already talked a little bit about NAD. So anything you want to say about
01:46:13 the NAD precursors, NR and NMN? To the listeners, there was a nice article
01:46:17 written in the New York Times recently about NAD, does it work? And they got a lot of experts. I
01:46:22 liked that article a lot. The experts were very good about making their disclosures. They have
01:46:27 a company, they don't have a company. So that was important. If you read the article, even those
01:46:31 experts say, does NAD again decline in normal aging to levels that become rate limiting?
01:46:40 And the answer seems largely no. Could the NAD precursors be used in a special setting?
01:46:46 Certain disease.
01:46:47 Certain disease. So there's a nice paper that came that liver regeneration can be boosted yesterday
01:46:52 by giving NAD supplements from a reputable group.
01:46:56 Sorry, what can be boosted?
01:46:57 liver regeneration. And the mechanisms and what they talked about kind of made sense to me. And
01:47:01 it's a nicely done study from a very reputable person at University of Pennsylvania, Joe Bauer.
01:47:06 So I like that study. So I can totally imagine. But liver regeneration after liver surgery or
01:47:11 after transplant surgery, I mean, it's pretty extreme cases. Pretty extreme, right? Same with,
01:47:15 could it work for anti-tumor immunity? Could it work under special conditions, et cetera, et cetera?
01:47:21 Absolutely. I'm open to that, but not for geoprotective. I just don't see how. And it's
01:47:26 based on mitochondrial dysfunction causes the mitochondria not to regenerate NAD because that's
01:47:31 what mitochondria do. Let's give NAD supplements. Yeah, which again, we should point out was
01:47:36 unsuccessful in the ITP. Okay, SS31. Now, this is actually pharmaceutical grade. This is treating,
01:47:42 what's it called? Bart syndrome. Bart syndrome. So this is because there is a mutation in a gene
01:47:48 that makes cardiolipin. Cardiolipin is found in mitochondria. Again, it is necessary for
01:47:54 cytochrome C oxidase that Otto Warburg did his research on, did his PhD on, and cardiolipin
01:48:01 levels dictate the efficiency of that enzyme to work. It uses the oxygen, makes ATP, etc.
01:48:08 These people have low amounts, and the FDA approved this SS31 as a way to stabilize the
01:48:15 little cardiolipin there to boost the efficiency of that enzyme. Some people argue that this SS31
01:48:21 interacts with a lot of proteins and overall is like a glue to the electron transport chain.
01:48:27 Here's another one, by the way. I would say we don't know the mechanism at all.
01:48:31 The drug is delivered intramuscularly?
01:48:33 I don't know how it's delivered. There is not an exact target of that drug,
01:48:38 or even a good putative hypothesis other than it's cardiolipid.
01:48:41 It's a drug that's shown a very, very weak effect in a very, very extreme and rare genetic disease,
01:48:47 but it is being touted as a mitochondrial boosting drug that should be taken by everybody.
01:48:54 What is the case for that? Again, is your mitochondrial rate limiting right now? No.
01:49:00 Well, or is cardiolipin rate limiting? Cardiolipin rate limiting. Yeah,
01:49:04 because the trial was done in cardiolipin-depleted conditions, and I would argue no. Again,
01:49:10 the drug could be repurposed in certain mitochondrial mutation patients, which might
01:49:15 have some problems. And I'm sure they're going to test it now in those settings. And I hope it works
01:49:19 because there, there is a deficiency. But for you and I, and for most people, I just don't see that.
01:49:26 How about methylene blue, which again has a very clear clinical indication. Beyond the clinical
01:49:31 indication, where do you see, is it something we should be just generally taking for mitochondrial
01:49:35 health? I'm glad you asked methylene blue. We're going to go back to my old friend cytochromoxidase
01:49:40 again. Isn't it amazing how all these supplements somehow interact with the things we've been
01:49:44 thinking about for years. So what it does is complex 1 has NADH. It goes to 3 and 4. 1 and 3
01:49:52 can generate a superoxide in H2O2. 4 cannot. It takes electrons from complex 1, methylene blue
01:50:00 from NADH, and it passes it on to complex 4, which gives it to oxygen. You bypass 1 and 3.
01:50:06 Sorry, that's 2.
01:50:07 Goes from 1. So usually you go from 1 and 3.
01:50:10 Oh, I thought it was 1, 2, 4.
01:50:12 So 1 and 2 both go into 3 of the electron transport chain. 3 goes to 4. I'm saying it
01:50:18 takes electrons from 1 and gives it to 4. That's what methylene blue does. Now 1 and 3 cannot
01:50:24 generate as many electrons for H2O2. So you can imagine diseases where H2O2 signaling is a problem.
01:50:33 Maybe methylene blue is a way to decrease those electrons from generating. But again,
01:50:38 And that's a hypothesis that I have, that that's how, if it could work, it would work,
01:50:43 but how much does it get in?
01:50:45 And as you know, it can inhibit monamine oxidases, which detoxify dopamine and serotonin.
01:50:51 And people on serotonin receptor uptakes, if you take too much of methylene blue, you
01:50:57 could get serotonin toxicity.
01:50:58 The levels that people take are much lower, but the biology hasn't been really worked
01:51:03 out.
01:51:03 Yeah.
01:51:03 And also, I think the therapeutic window of that drug is pretty narrow.
01:51:08 Very narrow for that reason. But it is interesting how it works with cytochrome oxidase in the
01:51:13 shuttle. There hasn't been enough research done on that, but the clinical trials haven't looked
01:51:18 great, I don't think, even for dementia, right? Not at all.
01:51:21 What about hyperbaric oxygen? I get asked about this all the time. It's amazing how many times
01:51:27 a week I get asked by somebody if they should buy a hyperbaric oxygen chamber.
01:51:31 No, please don't. People are both into high oxygen and low oxygen therapy. This one is for
01:51:38 sure bad. Outside of wound healing. Outside of wound healing. Yes, yes. I've worked a lot on
01:51:42 both of them. In fact, I got my whole career started on working on low oxygen, and then we
01:51:47 moved to high oxygen. What I can tell you in high oxygen now, to be fair, people do this for a short
01:51:52 amount of time, 60 minutes. If you take people in the ICU and you keep them on high oxygen,
01:51:58 I work in an ICU department. I'm not a physician, but I talk to them. They are dying to get those
01:52:03 people off high oxygen because the longer you keep somebody on high oxygen, and we've done
01:52:08 mice experiments on high oxygen, it causes senescence of your lung epithelial cells.
01:52:13 It causes cell death. There's been absolutely no benefit to the lung being exposed to that
01:52:18 level of oxygen. Now, is 60 minutes going to cause ulcerative? Probably not, but if you're doing it
01:52:24 all the time, I don't think it's going to cause cell death, but it might cause cell senescence.
01:52:29 And that's my one worry about it. I've worked with high oxygen, mainly in cell culture,
01:52:34 mainly in animals. It's nothing good. Do you realize why all of this attention
01:52:39 exists? Why are people so obsessed with hyperbaric oxygen? I think it comes back to
01:52:45 that Israeli study from a few years ago that looked at telomere length in this. And so,
01:52:50 unfortunately, if you were to incorrectly believe that telomere length has anything to do with
01:52:56 longevity, you would look at that study and say, but look, these people, they sat in hyperbaric
01:53:00 oxygen chambers, their telomeres got longer. Clearly that has an anti-aging benefit.
01:53:06 Many holes there. Starting with the telomere length.
01:53:09 Yeah, yeah, exactly. These are the kind of holes you can drive 18-wheel trucks through.
01:53:13 Aside from that study, is there anything else that is generating this belief?
01:53:18 Well, I think the other one is more oxygen, better for the mitochondria, maybe.
01:53:22 Okay. Let's talk about the other end of that spectrum.
01:53:25 Low oxygen.
01:53:26 Low oxygen therapy seems pretty good for athletes.
01:53:29 Yeah. So what's nice about low oxygen is that low oxygen, so high oxygen, there's no receptors for high oxygen.
01:53:36 Okay. High oxygen largely, if it's very high, we've shown this, causes oxidative stress at damaging levels.
01:53:43 So we can engineer a mouse and overexpress one of these antioxidant proteins, and the
01:53:49 mouse dies, and now the mouse lives longer.
01:53:51 The apoptosis cell death pathway, if we disengage that, the mice can survive hyperoxy.
01:53:56 So hyperoxy, and we can show it causes senescence cell death.
01:53:59 So we have pathways, but there's not a direct way hyperoxy is causing that.
01:54:04 I think it's just causing so much oxygen that you just make a lot of free radicals or destabilizing
01:54:09 the respiratory chain.
01:54:11 The low oxygen has a very nice system, which is called the HIF prolyl hydroxylist VHL.
01:54:18 Greg Semenza, Peter Radcliffe, Bill Kalin got the 2019 Nobel Prize on this.
01:54:23 So when we're hypoxic, this pathway gets activated.
01:54:27 One of the consequences is EPO, erythropoietin, which increases your hematocrit.
01:54:32 The other thing is the low oxygen increases your ventilation, right?
01:54:37 The pulmonary system vasoconstricts, those are independent of HIF.
01:54:40 years ago we showed, likely the sensor for those is mitochondrial. There's probably many other
01:54:46 things hypoxia does. Outside of an athlete who wants to increase red blood cell production,
01:54:52 is there any reason for a normal person? No. Well, remember, so an athlete's okay,
01:54:58 and the people on high altitude have mechanisms. But you know, a lot of people, especially the
01:55:02 elderly, get pulmonary edema when they go to altitude. This is well known. In fact, we've
01:55:07 studied hypoxia-induced pulmonary edema. So this idea that hypoxia is a panacea. Now, again,
01:55:13 could hypoxia be used in certain control settings, certain ways?
01:55:18 Like, should it be combined with chemotherapy, for example? Can it make a tumor cell more
01:55:22 susceptible to chemo or radiation?
01:55:24 Well, people argue that about hyperoxia as well, right? More oxygen and more free radicals. So
01:55:30 again, maybe in those sort of things, but just to take it for kicks because you're going to
01:55:35 live longer? I don't think so. All right, let's bring it back to cytochrome again,
01:55:40 red light therapy. Apparently, it hits cytochrome C oxidase, my enzyme. It's weird. So people say
01:55:46 that we always have a little bit of nitric oxide around in our bodies and NO can bind to cytochrome
01:55:52 oxidase and red light therapy would pop it off and make it more efficient. I actually don't know
01:55:57 how red light therapy is having its effects in vivo. By the way, the way we showed metformin
01:56:03 in complex one inhibition with NDI1, there is an ancient enzyme, not from yeast, but from C-squart.
01:56:10 If you inhibit complex one, you can override it with this alternative oxidase. So I have a way
01:56:16 to test that. Again, will I test red light theory? Well, unless it's having these clinical trials
01:56:21 that show something amazing, we have a good way to test that. I mean, the one thing where clinical
01:56:25 trials have definitely shown efficacy for red light is in skin rejuvenation. I feel like I used
01:56:32 to know how this worked. Is that working through collagen synthesis? Yeah. But again, years ago,
01:56:38 we showed that a little bit of H2O2 in skin cells and epithelial cells promoted their differentiation.
01:56:46 And people argue that red light therapy could increase a little bit of H2O2. And I wonder if
01:56:51 it's the mechanism we found years ago. So I wouldn't mind studying it. There's another
01:56:55 interesting benefit that you see in some of the trials in red light therapy, which is if you get
01:57:00 a significant enough portion of your body covered in red light, you see glucose uptake
01:57:04 enhanced. It's actually pretty interesting. So there was one study that looked at oral
01:57:08 glucose tolerance tests and the AUC, the area under the curve of glucose, went down when a
01:57:15 person had X amount of time of their back being hit with red light. Now, I remember when I read
01:57:20 this, it was actually a pretty significant reduction in AUC, but then I did sort of back
01:57:25 of the envelope math to see how it compared to exercising. And of course, it wasn't as much
01:57:29 glucose reduction as you would get from an equal amount of time of modest exercise,
01:57:34 but it was a lot relative to just laying there, given the fact that you compare it to the placebo.
01:57:39 I don't recall thinking through the mechanism. Wait, but doesn't that smell like maybe in the
01:57:45 back of the skin, maybe it inhibited cytochromoxidase, which would then force glucose uptake,
01:57:52 kind of like the gut metformin. Maybe as simple as that.
01:57:57 I remember wondering, and maybe they did, I don't know if they measured lactate,
01:58:00 but you would expect to see lactate go up if it was forcing more glycolysis.
01:58:04 Yeah. But minute you make a lactate in your blood, your heart loves to take up lactate.
01:58:09 Lots of tissues love to take up lactate. You'd have to make enough to overwhelm the other
01:58:14 cells. But maybe, maybe. So there's something there. Or again, we can engineer mice where we
01:58:20 can make a cytochrome oxidase homolog that is not red light responsive and test formally whether red
01:58:29 light therapy goes through modulating cytochrome oxidase. I mean, I think this is my big lesson
01:58:34 with all of these. Find the target, refractory the target, where does it go? And then let's look
01:58:41 at the human data and how it's efficacious. And all in all, when we just went through these things,
01:58:46 To me, metformin, I'm not saying people go run out and use it. It's still better
01:58:49 than all of these. It's approved. Lots of people use it. Maybe low-dose anti-inflammatory,
01:58:54 maybe cancer, very weak, definitely lower glucose. Take your citrulline and B12.
01:58:59 Yeah, I have a feeling I'm going to be getting a lot of questions about this from patients who
01:59:03 are going to be wondering, and I mean insulin-sensitive patients. We have lots of patients
01:59:07 that do take metformin, but I have to be honest with you, Nav, I'm really on the fence. I just
01:59:10 don't know, man. Me too. My family members ask it. The inflammation part, people like the best,
01:59:17 I think. But again, it has been the least studied. Yeah. Maybe that's an interesting case as I take
01:59:22 those patients that have persistently elevated CRPs that we otherwise can't come up with any
01:59:27 reason for, and maybe we do a metformin trial in those patients and see if we can knock down
01:59:31 some inflammation. And measure their clonal hematopoiesis as well. I was just about to say,
01:59:35 the chip is also a super interesting thing that I was unaware of. Anyway, now, this has been
01:59:39 absolutely fascinating. Can I make one other point? And this is a bit self-serving. I have
01:59:45 no conflict of interest, as I said. As we have gone through all this journey about what mitochondria
01:59:51 do, and especially all the supplements and all the big drugs, because they all end up doing
01:59:55 something. GLP-1, we didn't talk about SGL-2, metformin, all the supplements. They have
02:00:00 something to do with metabolism, something to do with mitochondria. 40 years ago, we started to
02:00:05 put money in the Human Genome Project, which I think has been a complete spectacular success.
02:00:10 We know the genome, all the sequencing technologies that came out. We've really gotten the granularity
02:00:16 of human genetics more and more. UK Biobank, all of this has come of age. We have never had a
02:00:22 moonshot for metabolism, whether it's the government, whether it's a foundation, whether
02:00:27 it's philanthropy. To be clear, places like Michael J. Fox Foundation for Parkinson's,
02:00:31 And I have a grant from them, and we think Parkinson's is a complex one disease, and
02:00:36 we're trying gene therapy with this NDI1, and they've given us some money, so I'm very
02:00:41 thankful to them, and we get some money from the government over the years to do all our
02:00:44 work, but it's not at scale, nothing like the Human Genome Project.
02:00:48 So my thing is, I know academia, there's some issues, but right now, we should be doubling
02:00:53 our efforts in science, especially in metabolism, which has been underfunded for 40 years.
02:01:00 I mean, you make a great point.
02:01:00 Why do you think that is, Nev? Is it simply that it got dwarfed by the genomic revolution?
02:01:05 It got dwarfed by the genomic revolution. And you remember when you were a student,
02:01:08 they said, now we know our genome. We're going to know everything about the human disease 30
02:01:12 years from now. This will not exist. Gene therapy. Well, it works great for monogenic diseases
02:01:17 and some other diseases, but everything else is idiopathic, unknown ideology.
02:01:22 Polygenic, yep.
02:01:23 Yeah, and also the toxins that we're exposed to more and more, like the Parkinson's one,
02:01:27 they all hit mitochondria. But there hasn't been a large scale. And people like me were early
02:01:32 adopters to metabolism. After the golden generation of metabolism, people all have passed away,
02:01:38 the Krebs of the world. And so in my world, there hasn't been that many. In the next generation, 0.99
02:01:43 there's a lot more. But I'm afraid they will probably walk away because there won't be enough
02:01:47 money for metabolism because it's dwarfed by the genomic revolution. So I really would like
02:01:53 people to make a push for the moonshot of metabolism.
02:01:58 But Nav, do you think it needs to be philanthropy or government? Do you not think this could be
02:02:02 biotech-driven?
02:02:03 The best case scenario would be all three. That's what the genomics people did. There's 0.91
02:02:07 biotech and genomics for sequencing machines that people buy. There's biotech for the drugs,
02:02:13 but the basic science comes from the government, and then you have the philanthropy
02:02:17 filling in all the holes. I'm just saying, yes, there is parts of it, but it isn't to scale.
02:02:22 And I know people are down on academia. I would argue we should double-triple our money for biomedical research. So the last 10 years that you talk about, which I completely agree, is what we want to save. And if we don't have a healthy population the last 10 years, we're going to bankrupt the nation because of healthcare costs. You know it and I know it as people live.
02:02:42 At the same time, I'm on record of saying this, and probably you'll get some flack for this,
02:02:47 you have the right, Peter, you do, and the taxpayers, and say, you know what? Are you
02:02:51 being as efficient, or are you being as innovative as you should be for the 21st century in academia's
02:02:57 current model? And I don't think we are. I think it's time that academia change how its business
02:03:03 model runs, but at the same time, give us three times as much money in return, okay? So I'm not
02:03:08 saying just give us money, and we'll keep on doing what we did. We need to change. We need a new model
02:03:12 a new system. I'm very open about it. I will encourage, I know you do notes, I hope you put
02:03:17 this, the grand people in science 10 years ago, people who ran Princeton, NIH director, Nobel
02:03:23 Prize, there's four of them, who wrote something called Rescuing the Biomedical Research Enterprise,
02:03:28 rescuing. They wrote like a white paper in the Proceedings of the National Academy of Sciences
02:03:33 because they're National Academy members, and they outlined what they thought were the problems
02:03:38 and solutions. I am not saying we all have to agree on their solutions or even the problems.
02:03:42 but it's a pretty good start. And that was 12 years ago.
02:03:45 And what came of it?
02:03:46 Nothing. Zero. We did the opposite, in my opinion.
02:03:49 What were some of the things that they pointed out?
02:03:51 No, some of the things about-
02:03:52 Like risk taking?
02:03:53 Risk taking, maybe different style labs, how the costs that the universities impinge on the 0.84
02:04:00 government. So in other words, having more skin in the game. So it's just not a revolving business
02:04:04 model. They had a lot of good ideas in there. And I'm not the right person who's thought about
02:04:09 all of this stuff. What I will say the biggest challenge is that, like a lot of things in the
02:04:15 U.S., it's become kind of an imperial power at the top, as opposed to decentralized labs and
02:04:23 decentralized divisions of biochemistry or medicine. If you're Google, you have 10 separate
02:04:29 divisions that answers to the top, but they're all kind of independent and decentralized.
02:04:33 We're way too centralized at every level.
02:04:36 And you're saying that not just at the NIH level, but at the university level?
02:04:40 Absolutely. At the biomedical research level, way, way, way, way too centralized.
02:04:45 There's cancer centers. Everything goes through the dean's office or the president's office.
02:04:50 You want a decentralized, you know this better than I do, decentralized-
02:04:54 They don't run like startups.
02:04:56 Yeah. So sorry for that.
02:04:58 No, no, no.
02:04:58 I think it's a really important thing.
02:04:59 I think that's a super, super interesting point.
02:05:01 And we have to keep on. And someone wants to support a moonshot of metabolism. Give me a call.
02:05:06 Not just for me, but for the field I'm talking about, okay?
02:05:09 All righty.
02:05:10 Thanks, man.
02:05:10 Great, thank you.
02:05:12 Thank you for listening to this week's episode of The Drive.
02:05:15 Head over to peteratiamd.com forward slash show notes
02:05:20 if you want to dig deeper into this episode.
02:05:23 You can also find me on YouTube, Instagram, and Twitter,
02:05:26 all with the handle peteratiamd.
02:05:28 You can also leave us a review on Apple Podcasts
02:05:31 or whatever podcast player you use.
02:05:34 This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice.
02:05:44 No doctor-patient relationship is formed.
02:05:47 The use of this information and the materials linked to this podcast is at the user's own risk.
02:05:53 The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
02:05:59 users should not disregard or delay in obtaining medical advice from any medical condition they
02:06:04 have, and they should seek the assistance of their healthcare professionals for any such
02:06:08 conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures
02:06:14 and the companies I invest in or advise, please visit peteratiamd.com forward slash about where
02:06:21 I keep an up-to-date and active list of all disclosures.
02:06:29 You